2020 ACR Convergence Study Sponsor Statements

0019. Lasting COVID-19 Impacts on US 0035. Distinct Biological Pathways in Both Rheumatology Practices Blood and Kidney Further Define Molecular Study Sponsor Statement: funded by Spherix Profiles Across Diverse Nephritides Global Insights, an independent market Study Sponsor Statement: Loqmane Seridi, research company Matteo Cesaroni, Qingxuan Song, Ashley Orillion, Frédéric Baribaud, Tatiana Ort, Sheng 0029. Urine Proteomic Classifiers Predict Renal Gao, and Jarrat Jordan are employees of Histological Activity and Chronicity Indices and Janssen Research & Development, LLC, Spring May Predict Treatment Response in House, PA, USA. Nephritis Study Sponsor Statement: This work was 0038. Protein Biomarkers May Differentiate supported by the Accelerating Medicines Responders and Non-Responders to Partnership (AMP) and , a Tumour Necrosis Factor Lupus Network. AMP is a public-private Inhibitor, in Ankylosing Spondylitis Patients - partnership (AbbVie Inc., Arthritis Foundation, The Bioefficacy SpA Study Bristol-Myers Squibb Company, Lupus Study Sponsor Statement: "I hereby confirm Foundation of America, Lupus Research that the Financial support for the Investigator Alliance, Merck Sharp & Dohme Corp., National Initiative Study BioEfficacySpA - Biomarkers Institute of Allergy and Infectious Diseases, identification of anti-TNF alfa agent’s efficacy in National Institute of Arthritis and Ankylosing Spondylitis patients using a Musculoskeletal and Skin Diseases, Pfizer Inc., proteomic analysis and mass spectrometry was Rheumatology Research Foundation, Sanofi and provided by AbbVie." Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and 0043. Geographical Disparity in Rheumatoid validating promising biological targets for Arthritis Disease Burden Independent of diagnostics and drug development Funding was Race/Ethnicity provided through grants from the National Study Sponsor Statement: Bristol-Myers Squibb Institutes of Health (UH2-AR067676, UH2- provided support for this study, but did not have AR067677, UH2-AR067679, UH2-AR067681, any input on the conduct or reporting of the UH2-AR067685, UH2- AR067688, UH2- study. AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, UM2- AR067678, and 0058. Drug Retention and Discontinuation of AR074096). Biological DMARDs and Novel Small Molecules: Data from the Singapore National Biologics Registry

1

Study Sponsor Statement: The Singapore Study Sponsor Statement: Research grant from National Biologics Register is funded by the Pfizer Chapter of Rheumatologists, College of Physicians, Academy of Medicine Singapore 0107. Effects of Abaloparatide on Modeling and which in turn receives funding from the Remodeling Based Bone Formation manufacturers of the biologic therapies Study Sponsor Statement: This study was included in this study. Pharmaceutical funded by Radius Health, Inc. companies providing funds to the Chapter of Rheumatologists do not have a role in the 0129. Glucocorticoid-Induced Osteoporosis in oversight of the study, data collection, data Patients with Chronic Inflammatory Rheumatic analysis or writing of abstracts or manuscripts, Diseases: A Multivariate Linear Regression but they do receive advance notice of Analysis Identifying Factors Affecting Bone publications on which they are able to Mineral Density comment. Study Sponsor Statement: Rh-GIOP is supported by a joint funding of Amgen, BMS, 0059. EHR-Supported Staff Protocol Improves Celgene, Generic Assays, GSK, Hexal, Horizon, Smoking Cessation in a Diverse Rheumatology Lilly, medac, Mundipharma, Novartis, Pfizer, Clinic: Results of Quit Connect Dissemination Roche, and Sanofi. Project Study Sponsor Statement: This study was 0132. Prevalence of Osteoporosis and Fragitlity funded by peer-reviewed institutional grant Fractures Is Not Different Between ACPA funding from Independent Grants for Learning Positive Patients Compared to ACPA Negative and Change (Pfizer). Funder played no role in Patients in a Real World Setting, Despite Longer the design of the research or the interpretation Disease Duration and Glucocorticoid-Treatment of results. Study Sponsor Statement: Rh-GIOP is supported by a joint funding of Amgen, BMS, 0101. Romosozumab After Celgene, Generic Assays, GSK, Hexal, Horizon, Improves Lumbar Spine and Maintains Total Hip Lilly, medac, Mundipharma, Novartis, Pfizer, Bone Mineral Density in Postmenopausal Roche, and Sanofi. Women with Low Bone Mass Study Sponsor Statement: Funding: Amgen, 0136. Significantly Improved Patient- Astellas, and UCB Pharma reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A 0104. Bone Effects of One-year Post Hoc Analysis of SF-36 and HAQ-DI from Treatment in Rheumatoid Arthritis Phase 3 Studies Study Sponsor Statement: Research grant from Study Sponsor Statement: Funding for FINCH 1 Pfizer and 2 was provided by Gilead Sciences, Inc. Funding for this analysis was provided by Gilead 0105. Use of Peripheral Quantitative Computed Sciences, Inc. The sponsors participated in the Tomography in the Assessment of Bone planning, execution, and interpretation of the Mineral Density in Anti-TNF-treated research. Rheumatoid Arthritis and Ankylosing Spondylitis Patients 0138. Alignment and Discordances in Treatment Perceptions and Shared Decision-

2

Making Among RA Patients and Rheumatology Inc. Funding for this analysis was provided by Care Teams Gilead Sciences, Inc. The sponsors participated Study Sponsor Statement: The study reported in the planning, execution, and interpretation of in this abstract was funded by an independent the research. educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. The grantors had 0145. Treat-to-Target in Rheumatoid Arthritis: no role in the study design, execution, analysis, Rates of Treatment Changes in Patients or reporting. Engaged with Care Management Services Compared to Historically Reported National 0140. Meaningful Within-Patient Change in Registry Based Estimates WOMAC Domains in Patients with Moderate- Study Sponsor Statement: Co-authors are To- Severe Osteoarthritis employees of CVS Health completed this Study Sponsor Statement: These studies were research as part of their work sponsored by Pfizer and Lilly. 0146. Patients’ Perceptions and Expectations 0141. Filgotinib Improved Work Productivity Towards the Role of Rheumatologists in the and Activity Impairment in Patients with Recommendations of Physical Activity’s Rheumatoid Arthritis and Inadequate Response Practice - A Cross-sectional Study Involving 308 to Methotrexate: Results from FINCH-1 Study Patients Living with Rheumatoid Arthritis in Study Sponsor Statement: Funding for the France FINCH 1 study was provided by Gilead Sciences, Study Sponsor Statement: Sanofi Genzyme Inc. Funding for this analysis was provided by funded the study. Gilead Sciences, Inc. The sponsors participated in the planning, execution, and interpretation of 0148. Perspectives on Treatment Burden for the research. Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis 0142. Filgotinib Improved Work Productivity Patients: A Qualitative Study and Activity Impairment in Patients with Study Sponsor Statement: This study was Rheumatoid Arthritis and Inadequate Response sponsored by Amgen Inc. to Biologic DMARDs: Results from the FINCH 2 Study 0149. How Stable Are Necessity Study Sponsor Statement: Funding for the Beliefs and Safety Concerns in the First Year of FINCH 2 study was provided by Gilead Sciences, RA? Inc. Funding for this analysis was provided by Study Sponsor Statement: The CATCH study Gilead Sciences, Inc. The sponsors participated was designed and implemented by the in the planning, execution, and interpretation of investigators and financially supported through the research. unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since 0143. Filgotinib Improved Work Productivity January 2007; AbbVie and Hoffmann-LaRoche and Activity Impairment in Patients with since 2011; Medexus since 2013; Eli Lilly Canada Rheumatoid Arthritis Who Are Methotrexate- since 2016, Merck Canada since 2017, Sandoz naïve: Results from the FINCH-3 Study Canada, Biopharmaceuticals since 2019 and Study Sponsor Statement: Funding for the Gilead Sciences Canada since 2020. Previously FINCH 3 study was provided by Gilead Sciences, funded by Janssen Biotech from 2011-2016,

3

UCB Canada and Bristol-Myers Squibb Canada funded by Merck Sharp & Dohme Corp., a from 2011-2018, and Sanofi Genzyme from subsidiary of Merck & Co., Inc., Kenilworth, NJ, 2016-2017. USA. The sponsor was involved in the study design, analysis, interpretation of data, and 0151. More Than Half of Newly Diagnosed RA development of the abstract. Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA 0168. Impact of Adalimumab (Humira) Therapy Characteristics, Symptoms, and Function in the on Ocular Inflammation, Selected Health Care Canadian Early Arthritis Cohort (CATCH) Resource Utilization, and Patient-Reported Study Sponsor Statement: The CATCH study Outcomes in Patients with Active Non- was designed and implemented by the infectious Intermediate, Posterior, or Panuveitis investigators and financially supported through in Routine Clinical Practice unrestricted research grants from: Amgen and Study Sponsor Statement: AbbVie funded the Pfizer Canada - Founding sponsors since study, contributed to the design, collection, January 2007; AbbVie Corporation and analysis, and interpretation of the data, and in Hoffmann-LaRoche since 2011; Medexus Inc. the writing, review, and approval of the since 2013; Eli Lilly Canada since 2016, Merck abstract. Medical writing support was provided Canada since 2017, Sandoz Canada, by Natalia Zhukovskaya, PhD, of ICON plc Biopharmaceuticals since 2019 and Gilead (North Wales, PA) and was funded by AbbVie. Sciences Canada since 2020. Previously funded by Janssen Biotech from 2011-2016, UCB 0170. Utilizing Design Thinking to Develop a Canada and Bristol-Myers Squibb Canada from Decision Aid for Patients with Psoriasis and 2011-2018, and Sanofi Genzyme from 2016- Psoriatic Arthritis 2017. Study Sponsor Statement: Funding source: A Pfizer Independent Learning and Change grant. 0154. Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data 0182. Chronic Kidney Disease Is from the ArthritisPower Registry Underestimated in Patients with Rheumatoid Study Sponsor Statement: This study was Arthritis – Real World Data Gathered from a funded by Eli Lilly and Company Network of Rheumatologists Study Sponsor Statement: This study was 0155. Changes in Patient-Reported Outcome funded by the RHADAR GbR (A Network of (PRO) Scores for Nausea and Fatigue Following Rheumatologists), Bahnhofstr. 32, 82152 Weekly Methotrexate Dose in a Real-World Planegg, Germany. RHADAR GbR has received Sample of RA and PsA Patients in the honoraria from UCB Pharma GmbH, Sandoz ArthritisPower Registry Deutschland / Hexal AG, and research support Study Sponsor Statement: This study was by Novartis Pharma GmbH. funded by Amgen, Inc. 0183. Incidence of Malignancies in Japanese 0163. Cost of Non-Persistence in the Treatment Patients with Rheumatoid Arthritis: Data from a with Subcutaneous Tumor Necrosis Factor- Large Japanese National Registry Alpha Inhibitors of Inflammatory Arthritis: A Study Sponsor Statement: This study was Propensity Score Matching Approach sponsored by Pfizer Inc. Medical writing Study Sponsor Statement: This study was support, under the guidance of the authors, was

4 provided by Gemma Turner, PhD, CMC Connect, Proposed, Higher Concentration Biosimilar (100 McCann Health Medical Communications, and mg/mL) Adalimumab, in Healthy Subjects was funded by Pfizer Inc, New York, NY, USA in Study Sponsor Statement: This study was accordance with Good Publication Practice funded by CELLTRION, Inc. (Incheon, Republic of (GPP3) guidelines (Ann Intern Med Korea). 2015;163:461-464). 0200. Predictors of Durable Clinical Response to 0187. Regional and Widespread Patterns of Tofacitinib 11 Mg Once Daily with or Without Non-articular Pain Are Common at RA Diagnosis Methotrexate in Patients with Rheumatoid and Contribute to Poor Outcomes at 12 Arthritis: Post Hoc Analysis of Data from a Months: A Prospective Study of Pain Patterns in Phase 3b/4 Methotrexate Withdrawal Study Canadians with RA Study Sponsor Statement: This study was Study Sponsor Statement: The CATCH study sponsored by Pfizer Inc. Medical writing was designed and implemented by the support, under the guidance of the authors, was investigators and financially supported through provided by Sarah Piggott, MChem, CMC unrestricted research grants from: Amgen and Connect, McCann Health Medical Pfizer Canada - Founding sponsors since Communications, and was funded by Pfizer Inc, January 2007; AbbVie Corporation and New York, NY, USA in accordance with Good Hoffmann-LaRoche since 2011; Medexus Inc. Publication Practice (GPP3) guidelines (Ann since 2013; Eli Lilly Canada since 2016, Merck Intern Med 2015;163:461-464). Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead 0201. A Multicenter, Randomized, Placebo- Sciences Canada since 2020. Previously funded controlled, Double-blind Phase 2 Study of by Janssen Biotech from 2011-2016, UCB SHR0302 versus Placebo in Chinese Subjects Canada and Bristol-Myers Squibb Canada from with Moderate to Severe Active Rheumatoid 2011-2018, and Sanofi Genzyme from 2016- Arthritis (RA) 2017. Study Sponsor Statement: Jiangsu Hengrui Medicine Co., Ltd 0192. Influence of Inflammatory and Non- inflammatory Rheumatic Disorders on the 0202. Safety Profile of for the Clinical and Biological Profile of Adult-onset Treatment of Rheumatoid Arthritis up to 8.4 Diabetes Years: An Updated Integrated Safety Analysis Study Sponsor Statement: Financial support Study Sponsor Statement: This abstract was was partly supplied by Bristol-Myers Squibb, Co. sponsored by Eli Lilly and Company, under Bristol-Myers Squibb, Co. was not involved in license from Incyte Corporation. the study design, data acquisition, data analysis, or writing of the manuscript. 0203. Safety of Baricitinib in Patients with Financial support was also supplied by the Rheumatoid Arthritis: Interim Report from All- "Societé Française de Rhumatologie" (SFR) Case Post‑Marketing Study in Clinical Use Study Sponsor Statement: The Study was 0199. A Phase 1, Randomized, Open-label, sponsored by Eli Lilly and Company. Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto- 0204. Pharmacokinetics and Safety of CT-P17, a injector and Pre-filled Syringe of CT-P17, a Proposed High Concentration (100 mg/mL)

5

Adalimumab Biosimilar, in Comparison with EU- Rheumatoid Arthritis Refractory to Tumor Approved Adalimumab and US-Licensed Necrosis Factor Inhibitors Adalimumab; Results of a Phase 1, Randomized, Study Sponsor Statement: This study was Double-blind, Three-arm, Single-dose Study in sponsored by Sanofi. Medical writing support H for this abstract was provided by Vojislav Study Sponsor Statement: This study was Pejović, PhD (Eloquent Medical Affairs, a sponsored by Celltrion, Inc. division of Envision Pharma Group), and funded by Sanofi. 0206. Fifty-Two Week Outcomes of Biologic- Naïve RA Patients Treated with Subcutaneous 0211. Efficacy and Safety of in Abatacept in Japanese Multicenter Patients from China, Brazil, and South Korea Investigational Study (ORIGAMI Study) with Rheumatoid Arthritis Who Have Had Study Sponsor Statement: This study was Inadequate Response to Conventional Synthetic funded by Ono Pharmaceutical Co., Ltd. and Disease-modifying Antirheumatic Drugs Bristol-Myers Squibb K.K. Study Sponsor Statement: AbbVie Inc. was the study sponsor, contributed to the study design, 0207. Upadacitinib Monotherapy in data collection, analysis and interpretation Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks 0212. Long-Term Safety and Effectiveness of Study Sponsor Statement: AbbVie sponsored Upadacitinib or Adalimumab in Patients with the studies and contributed to their design, as Rheumatoid Arthritis: Results at 72 Weeks well as to the analysis, collection, and Study Sponsor Statement: AbbVie funded the interpretation of the data study, contributed to study design, data collection, analysis & interpretation 0208. Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with 0213. Sustainability of Response to Inadequate Response to Methotrexate: 52- Upadacitinib as Monotherapy or in Week Results Combination Among Patients with Rheumatoid Study Sponsor Statement: Funding for FINCH 1 Arthritis and Prior Inadequate Response to was provided by Gilead Sciences, Inc. The Conventional Synthetic DMARDs sponsors participated in the planning, Study Sponsor Statement: AbbVie sponsored execution, and interpretation of the research. the studies and contributed to their design, as well as to the analysis, collection, and 0209. Upadacitinib as Monotherapy in Patients interpretation of the data with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 0214. Sustainability of Response Between Weeks Upadacitinib and Adalimumab Among Patients Study Sponsor Statement: AbbVie sponsored with Rheumatoid Arthritis and Prior Inadequate the studies and contributed to their design, as Response to Methotrexate well as to the analysis, collection, and Study Sponsor Statement: AbbVie sponsored interpretation of the data the studies and contributed to their design, as well as to the analysis, collection, and 0210. Long-term Safety and Efficacy of interpretation of the data over 5 Years in Patients with

6

0215. Incidence and Risk of Venous Thromboembolic Events Among Patients with 0220. Impact of Concomitant Glucocorticoids Rheumatoid Arthritis Enrolled in the on the Clinical Efficacy and Safety of Upadacitinib Clinical Trial Program Upadacitinib in Patients with Rheumatoid Study Sponsor Statement: AbbVie sponsored Arthritis: An Ad Hoc Analysis of Data from the studies and contributed to their design, as Three Phase 3 Studies well as to the analysis, collection, and Study Sponsor Statement: AbbVie funded this interpretation of the data study and participated in the study design, research, analysis, data collection, 0216. A Subgroup Analysis of Low Disease interpretation of data, reviewing, and approval Activity and Remission from Phase 3 Study of of the publication. All authors had access to Filgotinib in Patients with Inadequate Response relevant data and participated in the drafting, to Biologic DMARDs review, and approval of this publication. No Study Sponsor Statement: Funding for FINCH 2 honoraria or payments were made for was provided by Gilead Sciences, Inc. The authorship. Medical writing assistance was sponsors participated in the planning, provided by Frances Smith, PhD, of 2 the Nth, execution, and interpretation of the research. which was funded by AbbVie.

0217. Efficacy and Safety of Filgotinib in 0224. Efficacy of Long-term Treatment with Methotrexate-Naïve Patients with Rheumatoid Baricitinib 2 Mg in Patients with Active Arthritis: 52-Week Results Rheumatoid Arthritis Study Sponsor Statement: Funding for FINCH 3 Study Sponsor Statement: Authors who are was provided by Gilead Sciences, Inc. The employees of the study sponsor, Eli Lilly and sponsors participated in the planning, Company (Indianapolis, IN, USA), were involved execution, and interpretation of the research. in the study design, collecting and analyzing the data, interpreting the results, and preparing the 0218. Clinical Outcomes of Earlier versus abstract. Writing support was provided by Delayed Treatment of Iraqi Patients with Shannon E. Gardell, PhD of Evidera/PPD and Rheumatoid Arthritis with funded by Eli Lilly and Company Study Sponsor Statement: Funded by Pfizer 0226. Similar Efficacy of Sarilumab 0219. Is It Realistic to Stop Prednisone in Early Monotherapy (MONARCH) vs Sarilumab and Rheumatoid Arthritis? A Subanalysis from the Methotrexate Combination Therapy (MOBILITY BeSt and IMPROVED Studies B) in Patients with Rheumatoid Arthritis Study Sponsor Statement: The first year of the Study Sponsor Statement: This analysis was IMPROVED study was sponsored by AbbVie. The sponsored by Sanofi (Cambridge, MA, USA). BeSt study was supported by a government grant from the Dutch Insurance Companies, 0228. Impact of Upadacitinib or Adalimumab as with additional funding from Schering-Plough Initial Therapy on the Achievement of 48-Week B.V. and Janssen B.V. Both studies were Treatment Goals in Patients with Rheumatoid designed by the investigators. Data collection, Arthritis and Inadequate Response to trial management, data analysis and Methotrexate: Post Hoc Analysis of a Phase 3 preparation of the manuscript were performed Study by the authors. Study Sponsor Statement: AbbVie funded this

7 study and participated in the study design, Arthritis research, analysis, data collection, Study Sponsor Statement: AbbVie funded this interpretation of data, reviewing, and approval study; contributed to its design; participated in of the publication. All authors had access to data collection, analysis, and interpretation of relevant data and participated in the drafting, the data. review, and approval of this publication. No honoraria or payments were made for 0235. Safety and Biological Activity of authorship. Medical writing assistance was Rozibafusp Alfa in Subjects with Rheumatoid provided by Frances Smith, PhD, of 2 the Nth, Arthritis: Final Results of a Phase 1b which was funded by AbbVie. Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study 0229. Integrated Safety of Filgotinib in Patients Study Sponsor Statement: Amgen Inc. and with Moderately or Severely Active Rheumatoid AstraZeneca sponsored the phase 1b study Arthritis Receiving Treatment for up to 5.5 (NCT03156023) Years Study Sponsor Statement: Funding for DARWIN 0236. Safety and Usability of 1 and 2 was provided by Galapagos NV, and Administration by Auto-injector (AI) and Pre- funding for DARWIN 3, FINCH 1, 2, 3, and 4 was filled Syringe (PFS) in Patients with Active provided by Gilead Sciences, Inc. Funding for Rheumatoid Arthritis (RA): Patient-reported this analysis was provided by Gilead Sciences, Experience from a Multicenter, Randomized Inc. The sponsors participated in the planning, Controlled Pivotal Trial execution, and interpretation of the research. Study Sponsor Statement: This study is sponsored by Celltrion, Inc. 0230. Effect of Dose Escalation of Subcutaneous on Disease Activity 0237. Safety Profile of Upadacitinib up to 3 in Patients with Rheumatoid Arthritis in a Years of Exposure in Patients with Rheumatoid Randomized Controlled Trial Arthritis Study Sponsor Statement: This study was Study Sponsor Statement: AbbVie was the funded by Genentech, Inc. Genentech, Inc. was study sponsor, contributed to study design, involved in the design, execution and reporting data collection, analysis, and interpretation. of the study results. Support for third-party writing assistance, furnished by Health 0239. Adjudicated MACE and VTE in the Interactions, Inc., was provided by Genentech, Filgotinib RA Program: Integrated Analysis from Inc. Phase 2 and 3 Clinical Trials Study Sponsor Statement: Funding for DARWIN 0232. Safety and Effectiveness of Tocilizumab in 1 and 2 was provided by Galapagos NV, and Patients with Renal Insufficiency in the Non- funding for DARWIN 3 and FINCH 1, 2, 3, and 4 interventional Study ICHIBAN was provided by Gilead Sciences, Inc. Funding Study Sponsor Statement: The ICHIBAN study for this analysis was provided by Gilead was sponsered by Roche Pharma AG (Grenzach- Sciences, Inc. The sponsors participated in the Whylen, Germany) planning, execution, and interpretation of the research. 0234. Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid

8

0240. Long-term Safety and Efficacy of AR067677, UH2-AR067679, UH2-AR067681, Sarilumab over 5 Years in Patients with UH2-AR067685, UH2- AR067688, UH2- Rheumatoid Arthritis with 1 or >1 Prior Tumor AR067689, UH2-AR067690, UH2-AR067691, Necrosis Factor Inhibitor Failures UH2-AR067694, UM2- AR067678, and Study Sponsor Statement: This study was AR074096). The Hopkins Lupus Cohort is funded sponsored by Sanofi. Medical writing support by NIH AR 69572. for this abstract was provided by Vojislav Pejović, PhD (Eloquent Medical Affairs, a 0252. Corticosteroid and Opioid Use Remain division of Envision Pharma Group), and funded High in Systemic Lupus Erythematosus Patients by Sanofi. Receiving Biologic Therapy: A Retrospective Claims Database Analysis 0244. What Are the Early versus Late Predictors Study Sponsor Statement: The Study was for Systemic Lupus Erythematosus (SLE) sponsored by Eli Lilly and Company. Diagnosis? Study Sponsor Statement: This study uses data 0254. LLDAS (Low Lupus Disease Activity State) sources licensed by Janssen R&D, LLC. Some of and Remission Prevent Damage Accrual in the authors including YW, KL, GW, JL, DN, YZ, Systemic Lupus Erythematosus (SLE) Patients in KD and CK conducted the study as part of their a Primarily Mestizo Cohort employment with Janssen R&D, Janssen Study Sponsor Statement: This study was Scientific Affairs, and Janssen Pharm sponsored by Janssen. Technology. The abstract submission fee was funded by Janssen R&D. 0255. Effect of Removing Haemolytic and Gastrointestinal Activity from the Operational 0250. Lupus Nephritis and Renal Outcomes in Definition of the Lupus Low Disease Activity African-Americans: The Accelerating Medicines State – Implications for Use as a Trial Endpoint Partnership Cohort Experience Study Sponsor Statement: The Asia Pacific Study Sponsor Statement: This work was Lupus Collaboration received project support supported by the Accelerating Medicines grants from UCB Pharma, GlaxoSmithKline, Partnership (AMP) Rheumatoid Arthritis and Janssen, Bristol-Myers Squibb, and AstraZeneca. Lupus Network. AMP is a public-private partnership (AbbVie Inc., Arthritis Foundation, 0256. Patient Perspective of the Type 1 and 2 Bristol-Myers Squibb Company, Lupus SLE Model: A Qualitative Study Foundation of America, Lupus Research Study Sponsor Statement: This work was Alliance, Merck Sharp & Dohme Corp., National supported by the Pfizer Aspire Award. Institute of Allergy and Infectious Diseases, National Institute of Arthritis and 0272. Superior Discrimination Between LLDAS Musculoskeletal and Skin Diseases, Pfizer Inc., and DORIS Remission with Modification of Rheumatology Research Foundation, Sanofi and Prednisolone Dose Threshold Takeda Pharmaceuticals International, Inc.) Study Sponsor Statement: The Asia Pacific created to develop new ways of identifying and Lupus Collaboration receives research support validating promising biological targets for grants from AstraZeneca, Bristol-Myers Squibb, diagnostics and drug development Funding was Eli Lilly, EMD Serono, GlaxoSmithKline, Janssen, provided through grants from the National and UCB Pharma. Institutes of Health (UH2-AR067676, UH2-

9

0280. Compliance and Validation of Patient composed of Novartis, Pfizer, and Janssen to Reported Outcome Information Collected from advance digital biomarkers for psoriatic Lupus Patients Using a Mobile Application disease. The work within this abstract and its Study Sponsor Statement: Supported by a presentation here was conducted independently grant from Horizon Therapeutics. by co-authors from the non-profit research organizations Sage Bionetworks and PPACMAN. 0306. Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona 0323. Residual Symptoms in Patients with PsA Psoriatic Arthritis/Spondyloarthritis Registry Who Are in Very Low Disease Activity According Study Sponsor Statement: This study was to Physician Assessments sponsored by Corrona, LLC. Corrona has been Study Sponsor Statement: This was funded by supported through contracted subscriptions in NIH R01. the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli 0324. Comparative Responsiveness of Outcome Lilly and Company, Genentech, Gilead, Janssen, Measures in Psoriatic Arthritis: Preparation for Merck, Novartis, Ortho Dermatologics, Pfizer Pragmatic Trials Inc, Regeneron, Sanofi, and Sun. The abstract Study Sponsor Statement: Funded by NIH R01 was a collaborative effort between Corrona and Amgen with financial support provided by 0325. The Impact of PsA Disease Control Status Amgen. on Patient Treatment Satisfaction: Real-world Survey in US and Europe 0307. Longitudinal Analysis of the Patient Study Sponsor Statement: This study was Pathways to Diagnosis of Psoriatic Arthritis sponsored by Janssen. Study Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals 0326. Flares Among Patients with Psoriatic Corporation, East Hanover, NJ. Support for Arthritis (PsA) - Frequency and Impact on third-party writing assistance for this abstract, Patient Outcomes: Real-world Survey in the US furnished by Eric Deutsch, PhD, of Health and Europe Interactions, Inc, was provided by Novartis Study Sponsor Statement: This study was Pharmaceuticals Corporation, East Hanover, NJ. sponsored by Janssen.

0319. Target Outcomes in Psoriatic Arthritis: 0327. Skin Involvement in Psoriatic Arthritis Simultaneous Achievement of ACR50-Psoriasis (PsA) - The Incremental Impact of Psoriasis on Area and Severity Index 100 and Beyond: Quality of Life, Disability and Work Productivity: Insights from Open-Label, Assessor-Blinded Real-world Survey in US and Europe Study at Week 24 Study Sponsor Statement: This study was Study Sponsor Statement: The Study was sponsored by Janssen. sponsored by Eli Lilly and Company. 0328. Healthcare Utilization and Costs Among 0322. Development and Preliminary Validation Patients with Psoriatic Arthritis and Psoriasis in of Smartphone Sensor-based Measurement the United States – a Retrospective Study of Tools for Psoriatic Arthritis Claims Data from 2009 to 2020 Study Sponsor Statement: This work was Study Sponsor Statement: This study was funded by a pre-competitive consortium sponsored by Janssen.

10

Study Sponsor Statement: This study was 0329. Healthcare Utilization and Costs sponsored by Janssen. Associated with Functional Status in Patients with Psoriatic Arthritis 0337. Similar Impact of Psoriatic Arthritis and Study Sponsor Statement: This study was Rheumatoid Arthritis on Objective and funded by Novartis Pharmaceuticals Subjective Parameters of Hand Function Corporation, East Hanover, NJ. Support for Study Sponsor Statement: Novartis Pharma third-party writing assistance for this abstract, GmbH (Nuremberg, Germany) supported the furnished by Charli Dominguez, PhD, of Health funding of this research. Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ. 0341. Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose 0331. Work Absenteeism and Disability Psoriatic Arthritis and Ankylosing Spondylitis Associated with Psoriatic Arthritis and Psoriasis with High Specificity in the United States – A Retrospective Study of Study Sponsor Statement: The study was Claims Data from 2009 to 2020 funded by CARE Arthritis which played a role in Study Sponsor Statement: This study was the design and reporting of this research. sponsored by Janssen. 0345. Effectiveness and Safety of Apremilast in 0332. Improved Work Productivity Biologic-Naive versus Biologic-Experienced and Daily Activity in Patients with Psoriatic Patients with Psoriatic Arthritis in Real-World Arthritis: Results from a Phase 3 Trial Clinical Practice Settings in Germany: Interim Study Sponsor Statement: This study was Analysis of an Ongoing, Multicenter, sponsored by Janssen Prospective, Non-interventional Study Study Sponsor Statement: This study was 0334. Comparative Efficacy of Guselkumab in sponsored by Celgene and Amgen Inc. Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network 0346. Safety Profiles of versus Meta-Analysis Adalimumab: 52-Week Results from a Head-to- Study Sponsor Statement: This study was Head Comparison in Patients with Active sponsored by Janssen. Psoriatic Arthritis Study Sponsor Statement: The study was 0335. -17 Blockade Leads to Shifts sponsored by Eli Lilly and Company. from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very 0347. In Two Phase-3 Trials, Guselkumab Early and Established Psoriatic Arthritis Reduced Fatigue over 52 Weeks in Patients Study Sponsor Statement: The study was with Psoriatic Arthritis and Demonstrated supported by an unrestricted research grand Independent Treatment Effects on Fatigue from Novartis After Adjustment for Clinical Response (ACR20) Study Sponsor Statement: Employees of 0336. Anxiety and Depression in Psoriatic Janssen Research & Development, LLC, were Arthritis (PsA) - Prevalence and Impact on involved in designing the study, collecting and Patient Reported Outcomes: Real-World Survey analyzing the data, and writing and revising the in the US and Europe abstract.

11

Conventional Synthetic Disease-Modifying 0348. Biologics History and Sex Are Linked to Antirheumatic Drugs (DMARD) in Biologic Discontinuation in Axial DMARD-Naïve Patients with Psoriatic Arthritis: Spondyloarthritis: A Sub-Analysis of the Post- 52-Week Results Registration GO-Practice Study Study Sponsor Statement: The study was Study Sponsor Statement: MSD France entirely sponsored by Eli Lilly and Company. funded the GO-Practice study. 0353. Achievement of Sustained Remission and 0349. Pooled Safety Results from Two Phase-3 Low Disease Activity with Trials of Guselkumab in Patients with Psoriatic Improves Quality of Life and Physical Function Arthritis Through 1 Year in Patients with Psoriatic Arthritis: Results from Study Sponsor Statement: Employees of a Randomized Phase 3 Study Janssen Research & Development, LLC, were Study Sponsor Statement: The study was involved in designing the study, collecting and sponsored by Novartis Pharma AG, Basel, analyzing the data, and writing and revising the Switzerland abstract. 0354. How Do TNF-alpha-Inhibitors in Medical 0350. The Impact of Age and Time Since History Affect Patient Reported Outcomes and Diagnosis on Response to Treatment with Retention in Ankylosing Spondylitis Patients Secukinumab in Pooled Week 52 Data from 4 Treated with Secukinumab in Real World? – Phase 3 Studies in Patients with Ankylosing German Observational Study Spondylitis Study Sponsor Statement: The study was Study Sponsor Statement: Study Sponsors: sponsored by Novartis Pharma GmbH. Novartis Pharmaceuticals Corporation. The Academic advisors and Novartis personnel authors thank Amos Race, PhD, of designed the study. Novartis conducted the ArticulateScience LLC, Hamilton, NJ, for data analyses. All authors had access to the providing medical writing support/editorial data and vouch for the completeness and support, which was funded by Novartis accuracy of the data and analyses. Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good Publication Practice 0355. Collagen Turnover Markers Are guidelines (http://www.ismpp.org/gpp3). Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a 0351. -Treated Patients with Phase-3 Clinical Trial Psoriatic Arthritis in a Real-world Study: Similar Study Sponsor Statement: Employees of Clinical Responses and Treatment Persistence Janssen Research & Development were involved over One Year in Elderly and Younger Patients in designing the study, collecting and analyzing Study Sponsor Statement: Employees of the data, and writing and revising the abstract. Janssen Medical Affairs, LLC and Janssen Scientific Affairs, LLC, were involved in 0356. Improves Patient-Reported designing the study, collecting and analyzing Outcomes in Psoriatic Arthritis: 48-Week the data, and writing and revising the abstract. Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and 0352. Efficacy and Safety of Ixekizumab versus Disease Activity Adalimumab with and Without Concomitant Study Sponsor Statement: This study was

12 funded by UCB Pharma. Editorial services were provided by Costello Medical and funded by 0362. Patients with Psoriatic Arthritis Treated UCB Pharma. with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition 0358. Does Smoking Affect Secukinumab Impact on Their Health Related Quality of Life Treatment Outcomes and Safety in Patients Study Sponsor Statement: This study was with Ankylosing Spondylitis? – Real World Data funded by Janssen Research & Development, from German Observational Study LLC. The sponsor facilitated the study design, Study Sponsor Statement: The study was provided writing assistance and editorial sponsored by Novartis Pharma GmbH. support for the abstract, and reviewed and Academic advisors and Novartis personnel approved the abstract prior to submission. designed the study. Novartis conducted the data analyses. All authors had access to the 0363. Efficacy of Ixekizumab on Disease Activity data and vouch for the completeness and and Quality of Life in Patients with Active accuracy of the data and analyses. Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by 0359. Clinical Characteristics of Psoriatic Baseline CRP/Sacroiliac Joint MRI Status Arthritis Patients with Physician-Identified Study Sponsor Statement: The Study was Spondylitis, According to HLA-B27 Status: An sponsored by Eli Lilly and Company. Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry 0364. Subcutaneous Secukinumab 150 Mg Study Sponsor Statement: Employees of the Provides Sustained Relief in Total and Nocturnal Janssen Scientific Affairs, LLC, were involved in Back Pain, Morning Stiffness, Fatigue, and Low analyzing the data and writing and revising the Disease Activity in Patients with Active abstract. Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial 0360. Does Smoking Affect Secukinumab Study Sponsor Statement: The study was Treatment Outcomes and Safety in Patients sponsored by Novartis Pharma AG, Basel, with Psoriatic Arthritis? – Real World Data from Switzerland. Academic advisors and Novartis German Observational Study personnel designed the study. Statisticians Study Sponsor Statement: The study was employed by Novartis conducted the data sponsored by Novartis Pharma GmbH. analyses. All authors had access to the data and Academic advisors and Novartis personnel vouch for the completeness and accuracy of the designed the study. Novartis conducted the data and analyses. data analyses. All authors had access to the data and vouch for the completeness and 0366. Symptoms of Peripheral Arthritis Are accuracy of the data and analyses. Significantly Improved in Patients with Ankylosing Spondylitis Treated with 0361. Response to Treatment with Ixekizumab Secukinumab in Patients with Active Non-Radiographic Axial Study Sponsor Statement: This study was Spondyloarthritis Based on HLA-B27 Status and designed by the sponsor, Novartis Disease Duration Pharmaceuticals Corporation, in collaboration Study Sponsor Statement: Funded by Eli Lilly with the authors. The authors thank Amos Race, and Company. PhD, of ArticulateScience LLC, Hamilton, NJ,

13

USA for providing medical writing provided by M Hovenden and J Matsuura of support/editorial support, which was funded by ICON plc and was funded by AbbVie. Novartis Pharmaceuticals Corporation, East Hanover, NJ, in accordance with Good 0370. Guselkumab-Treated Patients Achieved Publication Practice guidelines Clinically Meaningful Improvement in Systemic (http://www.ismpp.org/gpp3). Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic 0367. Guselkumab Induces Sustained Reduction Arthritis Trial DISCOVER 1 in Acute Phase Proteins and Th17 Effector Study Sponsor Statement: This study was in Active Psoriatic Arthritis in Two funded by Janssen Research & Development, Phase-3 Clinical Trials (DISCOVER-1 and LLC. The sponsor facilitated the study design, DISCOVER-2) provided writing assistance and editorial Study Sponsor Statement: This study was support for the abstract, and reviewed and funded by Janssen Research & Development, approved the abstract prior to submission. LLC. The sponsor facilitated the study design, provided writing assistance and editorial 0371. Identifying Inadequate Response Among support for the abstract, and reviewed and Ankylosing Spondylitis Patients Prescribed approved the abstract prior to submission. Biologics in a Real-world Commercially Insured Adult Population in the United States 0368. Comparable Impact and Burden of Study Sponsor Statement: Eli Lilly and Company Disease of Psoriatic Arthritis Patients with funded this study Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results 0374. Neo-epitopes of Type I Collagen Can Be from a Prospective, Multicenter, Real-World Utilized as Translational Biomarkers for Skin Study in Patients Treated with Apremilast and Joint Turnover in Patients with Psoriasis Study Sponsor Statement: This study was and Psoriatic Arthritis funded by Celgene and Amgen Inc. Amgen Study Sponsor Statement: The work was acquired the worldwide rights to Otezla® sponsored by the Danish Research Foundation (apremilast) on November 21 2019. and The Innovation Foundation. Signe Holm Nielsen and Anne Sofie Siebuhr is 0369. Effect of Upadacitinib on Reducing Pain employed by Nordic Bioscience. Anne Christine in Patients with Active Ankylosing Spondylitis Bay-Jensen and Morten Karsdal are emplyees at and Inadequate Response to Nonsteroidal Anti- Nordic Bioscience and shareholders. inflammatory Drugs Study Sponsor Statement: AbbVie funded this 0377. Evaluation of Sex Differences in the study and participated in the study design, Efficacy and Safety of Tofacitinib in Patients research, analysis, data collection, with Active Psoriatic Arthritis: A Post Hoc interpretation of data, reviewing, and approval Analysis of Two Phase 3 Randomized Controlled of the publication. All authors had access to Trials relevant data and participated in the drafting, Study Sponsor Statement: • This study was review, and approval of this publication. No sponsored by Pfizer Inc. Medical writing support honoraria or payments were made for under the guidance of the authors was provided authorship. Medical writing support was by Jennifer Arnold, PhD, CMC Connect, McCann Health Medical Communications and was

14 funded by Pfizer Inc, New York, NY, USA in (GPP3) guidelines (Ann Intern Med accordance with Good Publication Practice 2015;163:461-464). (GPP3) guidelines (Ann Intern Med 2015;163:461-464). 0385. A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of 0378. Itch as the Major Mediator of the Effect Calcinosis in Patients with Systemic Sclerosis of Tofacitinib on Health-Related Quality of Life Study Sponsor Statement: United Therapeutics in Psoriatic Arthritis: A Mediation Analysis funded and sponsored this study. Authors had Study Sponsor Statement: This study was full editorial control and provided final approval sponsored by Pfizer Inc. Medical writing of all content. support, under the guidance of the authors, was provided by Eric Comeau, PhD, CMC Connect, 0388. Factors Prognostic of Greater Decline in McCann Health Medical Communications and Forced Vital Capacity in Patients with Systemic was funded by Pfizer Inc, New York, NY, USA in Sclerosis-Associated Interstitial Lung Disease accordance with Good Publication Practice (SSc-ILD): Data from the Placebo Group of the (GPP3) guidelines (Ann Intern Med SENSCIS Trial 2015;163:461-464). Study Sponsor Statement: Boehringer Ingelheim funded the SENSCIS trial and was 0379. Achievement of RAPID3 and cDAPSA involved in its design and implementation and Treatment Targets Is Associated with Control of in the interpretation of the data. Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in DMARD-Naive 0392. Prevalence and Survival of Systemic Patients Treated with Apremilast Sclerosis (SSc) and Associated Interstitial Lung Study Sponsor Statement: This study was Disease (ILD) in Ontario, Canada over 10 Years funded by Celgene. Additional analyses were Study Sponsor Statement: Funding for this funded by Amgen Inc. study was provided by Boehringer-Ingelheim (Canada) Limited. 0380. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate 0396. Safety and Efficacy of Subcutaneous Response to TNF Inhibitors: 3 Year Results from Tocilizumab in Systemic Sclerosis: Results from a Phase 3 Study the Open-Label Period of a Phase 3 Trial Study Sponsor Statement: The study was Study Sponsor Statement: F Hoffmann-La sponsored by Eli Lilly and company. Roche Ltd funded the study and was involved in conduct and reporting of the study. 0381. Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic 0405. Disease Activity and Quality-of-Life Arthritis Outcomes in Patients with Behçet’s Syndrome Study Sponsor Statement: This study was Who Achieved and Maintained Oral Ulcer sponsored by Pfizer Inc. Medical writing Complete Response with Apremilast Treatment support, under the guidance of the authors, was Study Sponsor Statement: This study was provided by Eric Comeau, PhD, CMC Connect, funded by Celgene. Additional analyses were McCann Health Medical Communications, and funded by Amgen Inc. was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice

15

0407. Achievement of Early and Sustained Baricitinib Complete Response of Oral Ulcers with Study Sponsor Statement: All cases were Apremilast Compared with Placebo in Patients enrolled in an IRB-approved natural history with Active Behçet’s Syndrome protocol. Funding for this study was provided in Study Sponsor Statement: This study was part by the Division of Intramural Research, funded by Celgene. Additional analyses were National Institute of Allergy and Infectious funded by Amgen Inc. Diseases, National Institutes of Health. The study is sponsored by Eli Lilly. Raphaela 0432. The Effect on Renal Function of the Goldbach-Mansky has received support under Complement C5a Receptor Inhibitor Avacopan CRADA agreements from Lilly, SOBI, Regeneron in ANCA-Associated Vasculitis and Novartis and Pfizer. Study Sponsor Statement: Study sponsored by ChemoCentryx, Inc. 0464. Assessment of the COVID-19 Pandemic from the Perspective of People with Rheumatic 0436. The Addressing Lupus Pillars for Health Musculoskeletal Diseases in Europe. Advancement (ALPHA) Project: Establishing Preliminary Results from the REUMAVID Study Consensus and Prioritization of Global Study Sponsor Statement: REUMAVID was Community Recommendations to Address funded by Novartis Pharma AG Major Challenges in Lupus Diagnosis, Care, Treatment and Research 0468. Concerns and Health-Related Behaviors Study Sponsor Statement: The ALPHA Project During the COVID-19 Pandemic in Patients with was launched in partnership with founding or Without Autoimmune Rheumatic Disease in partner EMD Serono Research & Development, a Large Physician Network Inc. (a business of Merck KGaA, Darmstadt, Study Sponsor Statement: This project has Germany) and through additional support by received sponsorship support from the Patient- GlaxoSmithKline. Aurinia Pharmaceuticals and Centered Outcomes Institute (PCORI), Eli Lilly Mallinckrodt Pharmaceuticals provide and Company, and Janssen Pharmaceutical. additional sponsorship. Funders had no role in the study design, analysis, or abstract creation 0447. Magnetic Resonance Imaging Characteristics in Patients with 0478. Increasing Awareness of Advocacy During Spondyloarthritis and Clinical Diagnosis of Heel Early Career – a Web-Based Educational Enthesitis: Screening Data from a Phase 3 Trial Program Study Sponsor Statement: The study was Study Sponsor Statement: 1. Web development sponsored by Novartis Pharma AG, Basel, supported by Medical Educational grant from Switzerland. Academic advisors and Novartis Pfizer, and supported by an unrestricted, personnel designed the study. Statisticians educational grant from Gilead Sciences, Inc. employed by Novartis conducted the data 2. CME and content supported by Association of analyses. All authors had access to the data and Women in Rheumatology. vouch for the completeness and accuracy of the data and analyses. 0482. Differential Influence of CDAI Components Based on Disease State in 0453. Monitoring of BK Reactivation and Long- Rheumatoid Arthritis Patients: Real World term Safety on JAK1/2 Inhibition with Results from a Rheumatoid Arthritis Cohort

16

Study Sponsor Statement: OBRI was funded by role in the study design, analysis, abstract peer reviewed grants from CIHR (Canadian preparation, or decision to submit. Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), 0497. Interleukin-23 Acts Directly on Podocytes Canadian Arthritis Network (CAN) and and Contributes to the Development of unrestricted grants from: Abbvie, Amgen, Glomerulonephritis Janssen, Medexus, Merck, Novartis, and Pfizer. Study Sponsor Statement: This study was Acknowledgment: Dr. Bombardier held a supported in part by a grant from Janssen Canada Research Chair in Knowledge Transfer Pharmaceuticals. for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology 0500. Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis 0484. Relationship Between Paraoxonase-1 Study Sponsor Statement: This research was Genotype, Activity, and Major Adverse funded with grants from the National Psoriasis Cardiovascular Events in Patients with Foundation, Pfizer, and the University of Utah. Rheumatoid Arthritis Receiving Tofacitinib Study Sponsor Statement: This study was 0504. Efficacy and Safety of Upadacitinib in sponsored by Pfizer Inc. Medical writing Patients with Active Psoriatic Arthritis and support, under the guidance of the authors, was Inadequate Response to Biologic Disease- provided by Jennifer Higginson, PhD, CMC Modifying Anti-Rheumatic Drugs: A Double- Connect, McCann Health Medical Blind, Randomized Controlled Phase 3 Trial Communications, and was funded by Pfizer Inc, Study Sponsor Statement: AbbVie Inc. was the New York, NY, USA in accordance with Good study sponsor, contributed to the study design, Publication Practice (GPP3) guidelines (Ann data collection, analysis and interpretation Intern Med 2015;163:461-464). 0505. Secukinumab Provides Sustained 0485. Non-obese Rheumatoid Arthritis Patients Improvements in Clinical and Imaging with Low Low-density Lipoprotein Have Higher Outcomes in Patients with Psoriatic Arthritis Coronary Atherosclerosis Burden, Greater and Axial Manifestations: Results from the Plaque Progression and Cardiovascular Event MAXIMISE Trial Risk Study Sponsor Statement: The study was Study Sponsor Statement: The sponsor sponsored by Novartis Pharma AG, Basel, provided only funding for the study conduct. Switzerland. Academic advisors and Novartis The sponsor was not involved in protocol personnel designed the study. Statisticians crafting, data collection, analysis or manuscript employed by Novartis conducted the data drafting. analyses. All authors had access to the data and vouch for the completeness and accuracy of the 0489. Prevalence, Incidence, and Cause-Specific data and analyses. Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients 0506. Efficacy and Safety of Guselkumab, a with Rheumatoid Arthritis: A Nationwide Specific to the p19- Cohort Study Subunit of Interleukin-23, Through Week 52 of Study Sponsor Statement: The sponsor had no a Phase 3, Randomized, Double-blind, Placebo- controlled Study Conducted in Biologic-naïve

17

Patients with Active Psoriatic Arthritis Study Sponsor Statement: Genentech provided Study Sponsor Statement: This study was funding for mass spectrometry, but did not funded by Janssen Research & Development, participate in the design of the study or the LLC. The sponsor facilitated the study design, interpretation of the results provided writing assistance and editorial support for the abstract, and reviewed and 0516. Characteristics of Giant Cell Arteritis approved the abstract prior to submission. Flares After Successful Treatment with Tocilizumab: Results from the Long-Term 0507. Comparison of Secukinumab versus Extension of a Randomized Controlled Phase 3 Adalimumab Efficacy by Sex in Psoriatic Trial Arthritis from a Phase 3b, Double-blinded, Study Sponsor Statement: F Hoffmann-La Randomized, Active-controlled Study Roche Ltd funded the study and was involved in Study Sponsor Statement: The study was conduct and reporting of the study. sponsored by Novartis Pharma AG, Basel, Switzerland 0533. Characterization of Older Male Patients with a Fragility Fracture 0508. Maintenance or Achievement of Minimal Study Sponsor Statement: This research was Disease Activity Following Therapy funded by Radius Health, Inc. Optimization with Adalimumab or Methotrexate in Patients with Psoriatic 0541. Suboptimal Vaccination Coverage with Arthritis: Results from Part 2 of a Randomized, Influenza, Pneumococcal and Herpes Zoster Open-Label Phase 4 Study Vaccines Among Adult Patients with Study Sponsor Statement: AbbVie funded this Autoimmune Inflammatory Rheumatic Diseases study and participated in the study design, in a Nationwide Health Care Plan research, analysis, data collection, Study Sponsor Statement: AbbVie participated interpretation of data, reviewing, and approval in the study design; collection, analysis, and of the publication. All authors had access to interpretation of data; writing, reviewing, and relevant data and participated in the drafting, approving this abstract for submission. All review, and approval of this publication. No authors had access to the data; participated in honoraria or payments were made for the development, review, and approval of the authorship. Medical writing support was abstract; and agreed to submit this abstract to provided by Jamie Urbanik, PharmD of AbbVie. the ACR convergence for consideration as a poster or oral presentation. AbbVie funded the 0512. Efficacy of Apremilast for the Treatment research for this study. of Manifestations of Behçet’s Syndrome Other Than Oral Ulcers, Including Skin Lesions and 0546. Stepping up for Inflammatory Arthritis Arthritis (SUFIA): A Pilot Trial to Test Behavioral Study Sponsor Statement: This study was Economics Strategy to Increase Physical Activity funded by Celgene. Additional analyses were in Inflammatory Arthritis funded by Amgen Inc. Study Sponsor Statement: Sponsored by internal pilot grant 0513. Mass Spectrometry Identifies Novel Biomarkers in Giant Cell Arteritis, Useful in 0567. Rheumatologist’s Perception of the Patients on Interleukin-6 Receptor Blockade Efficacy, Safety and Willingness to Prescribe

18

Infliximab and Use Alternate Drug Supply 0583. Cost of Illness in Patients with Psoriasis Programs to Lower Cost of Rheumatoid and Psoriatic Arthritis Arthritis Care Study Sponsor Statement: This project has been Study Sponsor Statement: Co-authors are supported by an unrestricted grant from employees of CVS Health and completed this Celgene. The design, analysis and interpretation research as part of their work. of results has been done independently of Celgene. 0573. Effects of Successive Switches of Two Different Biosimilars of Etanercept on 0584. Total Cost of Care for Patients with Outcomes in Inflammatory Rheumatic Diseases Rheumatoid Arthritis in Daily Practice Study Sponsor Statement: Co-authors are Study Sponsor Statement: This work was employees of CVS Health and completed this supported by Hexal. The Investigators retained research as part of their work. full control of scientific and analytic content, and had final editorial responsibility. 0593. Patient Characteristics and Factors Affecting Decision-Making Regarding Total 0576. Medical Savings of Timely Rheumatoid Knee Replacement by Different Types of Arthritis Diagnoses Physicians Treating Patients with Knee OA Study Sponsor Statement: Co-authors are Study Sponsor Statement: Samumed, LLC was a employees of CVS Health and completed this sponsor of the research. Drs. Bedenbaugh, Lee, research as part of their work. Kenndy, and Tambiah are employees of Samumed and both participated in the research 0579. Risk Factors of Nonadherence in New and in developing and writing the abstract. Rheumatoid Arthritis Patients Study Sponsor Statement: Co-authors are 0648. Dual Energy CT Has Additional Prognostic employees of CVS Health and completed this Value over Clinical Measures in Gout Including research as part of their work. Tophi: Best Evidence Synthesis Study Sponsor Statement: Sally Stauder was a 0580. Risk of Severe Acute Localized Reactions summer intern working at Horizon Therapeutics for Different Intra-Articular Hyaluronic Acid during the initation of this work. Her supervisor, Knee Injections in a Real World Setting Dr. Paul Peloso is a full-time employee of Study Sponsor Statement: One of the authors is Horizon Therapeutics. an employee of the funding organization; he provided input into the design of the study and 0649. A Multicenter, Open-Label, Efficacy and reviewed the abstract, but played no role in the Safety Study of Pegloticase in Patients with collection, management, and statistical analysis Uncontrolled Gout Who Have Undergone of the data. Kidney Transplantation: Early Data Report Study Sponsor Statement: Horizon 0581. A Proposed Economic Framework to Therapeutics funded the study, contributed to Model the Consequences of Psoriatic Arthritis the design, collection, analysis, and Disease Domains interpretation of the data, and in the writing, Study Sponsor Statement: This study was review, and approval of the abstract. sponsored by Amgen Inc.

19

0662. Cause-Specific Mortality in Patients with the design, collection, analysis, and Gout in the Veteran’s Health Administration: A interpretation of the data, and in the writing, Matched Cohort Study review, and approval of the abstract. Study Sponsor Statement: Funding for the study was provided by Horizon Therapeutics. 0681. Gout and Serum Urate Levels Are The study sponsor had no role in the planning or Associated with Lumbar Spine Monosodium execution of the study and played no role in Urate Deposition and Chronic Low Back Pain: A preparing the report for submission. Dual-Energy CT Study Study Sponsor Statement: This study is an 0665. Trends in investigator initiated study that is funded by Immunomodulation/pegloticase Co-therapy Horizon Therapeutics. Horizon played no role in from 2015-2019: A Claims Database Study the design or performance of the study. Study Sponsor Statement: The study was funded by Horizon Therapeutics. 0683. Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with 0673. Gout Is an Independent Risk Factor for Uncontrolled Gout Receiving Pegloticase and Undergoing an Amputation Procedure Co-treatment of Methotrexate Study Sponsor Statement: The Study was Study Sponsor Statement: Horizon sponsored by Horizon Therapeutics Therapeutics funded the study, contributed to the design, collection, analysis, and 0674. Disease Control of Hyperuricemia Newly interpretation of the data, and in the writing, Detected by Medical Check-up: A Retrospective review, and approval of the abstract. Cohort Study of Health Insurance Claims Data in Japan 0685. The Impact of Azathioprine on the Study Sponsor Statement: This study was Frequency of Persistent Responsiveness to supported by Teijin Pharma Limited. The Pegloticase in Patients with Chronic Refractory sponsor participated in the design of the study, Gout statistical analysis, and the interpretation of Study Sponsor Statement: Funded by a data. research grant from Horizon Therapeutics

0675. AR882, a Potent and Selective Uricosuric 0690. AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Agent, Significantly Reduced Serum Urate in Levels Following Multiple Ascending Once-Daily Patients with Gout in a Phase 2a Study Doses in Healthy Subject Volunteers Study Sponsor Statement: This study was Study Sponsor Statement: The study was sponsored by Arthrosi Therapeutics Inc sponsored by Arthrosi Therapeutics Inc. 0691. Denosumab Did Not Improve 0677. A Multicenter, Efficacy and Safety Study Computerized Tomography Erosion Scores of Methotrexate to Increase Response Rates in When Added to Intensive Urate-Lowering Patients with Uncontrolled GOut Receiving Therapy in Gout: Results from a Pilot Study Pegloticase (MIRROR): 12-Month Results of an Study Sponsor Statement: The project has been Open-Label Study funded by Amgen Inc (USA), however, the Study Sponsor Statement: Horizon funders had no role in the study design, data Therapeutics funded the study, contributed to

20 collection, analysis, reporting, or the decision to Arthritis with Poorer Physical Function and submit for publication. Higher Physician Global Assessment Study Sponsor Statement: Pfizer Inc. funded 0713. Longitudinal Effectiveness of Abatacept this investigator-initiated study. in JIA: Results from an Ongoing JIA Registry Study Sponsor Statement: This study was 0756. Increased Risk of Hospitalization in sponsored by Bristol-Myers Squibb Company Patients with RA Who Are ACPA Positive and Shared Epitope Positive 0714. Response to Abatacept in JIA Categories: Study Sponsor Statement: This abstract was Results from the PRCSG/PRINTO JIA Abatacept funded by Bristol-Myers Squibb Company Phase IV Registry Study Sponsor Statement: The study is 0764. Uncovering Novel Biomarkers for sponsored by Bristol-Myers Squibb Company Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on 0715. JIA-ACR50 Response as a Predictor of Synovium and Blood Gene Expression Data Minimal Disease Activity in Patients Aged 2–17 Study Sponsor Statement: This work was in Years with Polyarticular-Course JIA Treated part funded by Pfizer. The funders had no role in with SC Abatacept study design, data collection and analysis, Study Sponsor Statement: This study was decision to publish, or preparation of the sponsored by Bristol-Myers Squibb Company abstract.

0738. Systemic Administration of Novel 0788. Rigorous Plasma Microbiome Analysis Hydroxyl Dendrimers to Target Inflammation in Method Enables Disease Association Discovery Arthritic Tissues Study Sponsor Statement: This work was Study Sponsor Statement: Ashvattha supported by grants from the National Therapeutics funded this research. Institutes of Health: R01 AI128864 and supplemental grant (Jiang), R01 CA213290 (Li), 0743. Higher Baseline Fine-Specificity ACPAs R01 AR071410 and R01 AR071947 (Tsao), P60 Predict Greater Treatment Response with AR062755 (Gilkeson, Kamen and Oates), UL1 Abatacept + MTX versus MTX Monotherapy in RR029882, the Medical Research Service at the Seropositive RA: A Post Hoc Analysis Ralph H. Johnson VA Medical Center Merit Study Sponsor Statement: This study was grant VA CSRD MERIT (CX001211, Gilkeson), the funded by Bristol-Myers Squibb Company Biorepository & Tissue Analysis Shared Resource, and Hollings Cancer Center, Medical 0749. Locating Cellular Subsets in Rheumatoid University of South Carolina (P30 CA138313), Arthritis Synovium Using CO-Detection by R01LM012517 (Alekseyenko), R21TR002513 IndEXing (CODEX) (Alekseyenko), P30AR072582 (Gilkeson, Kamen Study Sponsor Statement: The sponsor and Oates), AR067459 (Kamen), AR068406 collaborated with UC San Diego in the (Kamen), RR001070 (Kamen), UL1 TR001450, generation and interpretation of data. No R01CA164964, U54CA210962, P50AR070591, learners were involved with the project. the National Natural Science Foundation of China (81772185, Huang), and the Lupus 0751. Serum -Alpha Levels Could Research Alliance and Scleroderma Foundation Help Identify a Subgroup of Rheumatoid (Tsao).

21

0801. The Comparative Effectiveness of 0793. Topological Laser Capture Microscopy Abatacept versus TNF Inhibitors in Patients (LCM)-RNAseq to Map the Rheumatoid Arthritis Who Are ACPA Positive and Have the Shared (RA) Synovial Transcriptome Epitope: Results from a US National Study Sponsor Statement: The sponsor Observational Study collaborated with UC San Diego in the Study Sponsor Statement: This study was generation and interpretation of data. No sponsored by Corrona, LLC. Corrona is learners were involved with the project. supported through contracted subscriptions with multiple pharmaceutical companies. The 0798. A Randomized, Double-blind Phase 3 abstract was a collaborative effort between Study Comparing the Efficacy, Safety and Corrona and Bristol-Myers Squibb Company Immunogenicity of PF-06410293 (Abrilada™), with financial support provided by Bristol-Myers an Adalimumab (ADL) Biosimilar, and Reference Squibb Company. ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92 0802. Real-World DMARD Experience and Study Sponsor Statement: The study sponsor Outcomes for Rheumatoid Arthritis Patients in monitored patient data collected by the Japan: Effectiveness investigators for completeness and Study Sponsor Statement: Corrona has been acceptability throughout the course of the supported through contracted subscriptions in study; generated and validated statistical the last 2 years by AbbVie, Amgen, Boehringer analyses; provided funding for medical writing Ingelheim, Bristol-Myers Squibb, Celgene, Eli and editorial support; and reviewed the final, Lilly and Company, Genentech, Gilead, Janssen, author-approved version for intellectual Merck, Novartis, Ortho Dermatologics, Pfizer property protection. Inc., Regeneron, and Sun.

0799. Effectiveness of Electronic Drug 0803. Real-World DMARD Experience and Monitoring Feedback in Order to Increase Outcomes for Rheumatoid Arthritis Patients in Adherence in RA Patients Starting with a Japan: Safety Biological DMARD Study Sponsor Statement: Corrona has been Study Sponsor Statement: A grant was received supported through contracted subscriptions in from Pfizer. Pfizer played no part in the design, the last 2 years by AbbVie, Amgen, Boehringer conduct or analysis of the results. Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Genentech, Gilead, Janssen, 0800. A Randomized, Double-Blind, Phase 3 Merck, Novartis, Ortho Dermatologics, Pfizer Study to Compare the Efficacy and Safety of a Inc., Regeneron, and Sun. Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference 0805. The PROPER Study: Results of the First Adalimumab in Patients with Moderate-to- Interim Analysis of a Pan-EU Real-World Study Severe Active Rheumatoid Arthritis of SB5 Biosimilar Following Transition from Study Sponsor Statement: This study was Reference Adalimumab in Patients with funded by CELLTRION, Inc. (Incheon, Republic of Rheumatoid Arthritis, Axial Spondyloarthritis or Korea). Psoriatic Arthritis Study Sponsor Statement: Biogen International

22

GmbH (Baar, Switzerland) funded and Observational Study sponsored this study Study Sponsor Statement: This study was sponsored by Corrona, LLC. Corrona is 0808. Time to Discontinuation of Tofacitinib supported through contracted subscriptions and TNF Inhibitors in Rheumatoid Arthritis with multiple pharmaceutical companies. The Patients with and Without Methotrexate: Real abstract was a collaborative effort between World Results from a Rheumatoid Arthritis Corrona and Bristol-Myers Squibb Company Cohort with financial support provided by Bristol-Myers Study Sponsor Statement: OBRI was funded by Squibb Company. peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry 0825. Sex Differences in the Efficacy and Safety of Health and Long-Term Care (MOHLTC), of Tofacitinib in Rheumatoid Arthritis Patients: Canadian Arthritis Network (CAN) and A Post Hoc Analysis of Phase 3 and Long-Term unrestricted grants from: Abbvie, Amgen, Extension Trials Janssen, Medexus, Merck, Novartis, and Pfizer. Study Sponsor Statement: This study was Acknowledgment: Dr. Bombardier held a sponsored by Pfizer Inc. Medical writing support Canada Research Chair in Knowledge Transfer under the guidance of the authors was provided for Musculoskeletal Care and a Pfizer Research by Christina Viegelmann, PhD, CMC Connect, Chair in Rheumatology McCann Health Medical Communications, and was funded by Pfizer Inc, New York, NY, USA in 0809. Comparative Effectiveness of Intravenous accordance with Good Publication Practice Golimumab vs Dose-Escalated Infliximab in a (GPP3) guidelines (Ann Intern Med Real World Population of Rheumatoid Arthritis 2015;163:461-464). Patients: 52-Week Data from the AWARE Study Study Sponsor Statement: This study was 0826. Clinical Responses and Patient Flow over funded by Janssen Research & Development, 2 Years of Treatment with Abatacept, Including LLC. The sponsor facilitated the study design, Dose De-Escalation, in Patients with Early, MTX- provided writing assistance and editorial Naïve, ACPA+ RA: Results from a Phase IIIb support for the abstract, and reviewed and Study approved the abstract prior to submission Study Sponsor Statement: This study was sponsored by Bristol-Myers Squibb Company 0811. Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab 0827. Comparative Clinical Efficacy of Study Sponsor Statement: This study was Sarilumab versus Upadacitinib over 12 Weeks: sponsored by Sanofi. Medical writing support Matching-Adjusted Indirect Comparison was provided by Vojislav Pejović, PhD (Eloquent Analysis Medical Affairs, a division of Envision Pharma Study Sponsor Statement: This study was Group), and funded by Sanofi. sponsored by Sanofi. Medical writing support was provided by Richard J Hogan, PhD 0824. The Comparative Effectiveness of (Eloquent Medical Affairs, division of Envision Abatacept versus Tofacitinib After 6 Months of Pharma Group), and funded by Sanofi. Treatment in Patients with RA Who Were Anti- citrullinated Protein Antibody Positive at 0828. Clinical and Functional Response to Baseline: Results from a US National Tofacitinib in Patients with Rheumatoid

23

Arthritis: Probability Plot Analysis of Results Years Compared with 65 Years or Older at from a Phase 3b/4 Methotrexate Withdrawal Registry Enrollment: Real World Results from a Study Rheumatoid Arthritis Cohort Study Sponsor Statement: This study was Study Sponsor Statement: Funding: OBRI was sponsored by Pfizer Inc. Medical writing funded by peer reviewed grants from CIHR support, under the guidance of the authors, was (Canadian Institute for Health Research), provided by Anthony G. McCluskey, CMC Ontario Ministry of Health and Long-Term Care Connect, McCann Health Medical (MOHLTC), Canadian Arthritis Network (CAN) Communications, and was funded by Pfizer Inc, and unrestricted grants from: Abbvie, Amgen, New York, NY, USA in accordance with Good Aurora, Bristol-Meyers Squibb, Celgene, Publication Practice (GPP3) guidelines (Ann Hospira, Janssen, Lilly, MedexusMerck, Intern Med 2015;163:461-464). Novartis, Pfizer, Roche, Sanofi, & UCB Acknowledgment: Dr. Bombardier held a 0829. International Comparison of Japanese Canada Research Chair in Knowledge Transfer and US Cross Country Utilization of RA for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology Study Sponsor Statement: Corrona has been supported through contracted subscriptions in 0832. PROSARA - A Prospective, Multicenter, the last 2 years by AbbVie, Amgen, Boehringer Noninterventional Study to Evaluate the Safety Ingelheim, Bristol-Myers Squibb, Celgene, Eli and Effectiveness of Sarilumab for the Lilly and Company, Genentech, Gilead, Janssen, Treatment of Active Rheumatoid Arthritis in Merck, Novartis, Ortho Dermatologics, Pfizer Regular Care in Germany Inc., Regeneron, and Sun. Study Sponsor Statement: This study was sponsored by Sanofi. Amy Praestgaard, MS, of 0830. Discontinuation Rate of Tofacitinib Is Sanofi provided statistical review. Medical Similar When Compared to TNF Inhibitors in writing support was provided by Richard J Rheumatoid Arthritis Patients: Real World Hogan, PhD (Eloquent Medical Affairs, a Results from a Rheumatoid Arthritis Cohort division of Envision Pharma Group), and was Study Sponsor Statement: Funding: OBRI was funded by Sanofi. funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), 0834. Is Disease Severity Greater Among Ontario Ministry of Health and Long-Term Care Patients with Rheumatoid Arthritis Who (MOHLTC), Canadian Arthritis Network (CAN) Receive a Newly Approved Biologic? Real-world and unrestricted grants from: Abbvie, Amgen, US Experience with Sarilumab from the ACR Aurora, Bristol-Meyers Squibb, Celgene, RISE Registry Hospira, Janssen, Lilly, MedexusMerck, Study Sponsor Statement: This study was Novartis, Pfizer, Roche, Sanofi, & UCB sponsored by Sanofi. Medical writing support Acknowledgment: Dr. Bombardier held a was provided by Vojislav Pejović, PhD (Eloquent Canada Research Chair in Knowledge Transfer Medical Affairs, division of Envision Pharma for Musculoskeletal Care and a Pfizer Research Group), and funded by Sanofi. This data was Chair in Rheumatology supported by the ACR’s RISE Registry. However, the views expressed represent those of the 0831. Sociodemographic, Disease, and authors, not necessarily those of the ACR. Medication Profile of RA Patients Under 65

24

0840. Amelioration of Immune Complex- 0854. Mortality and Adverse Events of Special Mediated Glomerulonephritis via CD6 Interest in Adult Patients with Systemic Lupus Modulation Erythematosus Receiving Intravenous Study Sponsor Statement: Equillium sponsored : A Post Hoc Descriptive Summary of the study. Serious Psychiatric Events Study Sponsor Statement: We acknowledge the 0841. CD6 Modulation Ameliorates Kidney and BASE Study Group. Study funding: GSK Skin Disease in a Spontaneous Murine Lupus Model 0857. Agreement of Hydroxychloroquine Blood Study Sponsor Statement: Equillium funded the Levels Between a University and Commercial study. Laboratory Study Sponsor Statement: Exagen Diagnostics 0848. Delineation of a Proinflammatory paid for the commercial hydroxychloroquine Profile Targeted by 1/2 blood level assays. Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial 0859. Biomarkers of B-cell Depletion and Study Sponsor Statement: The study was Response in a Randomized, Controlled Trial of sponsored by Eli Lilly and Company. Obinutuzumab for Proliferative Lupus Nephritis Study Sponsor Statement: This study was 0849. Herpes Zoster Events with in funded by F. Hoffmann-La Roche. F. Hoffmann- Patients with Active SLE: An Integrated Analysis La Roche was involved in the design, execution of Phase 2 and Phase 3 Trials and reporting of the study results. Study Sponsor Statement: This study was sponsored by AstraZeneca. Writing assistance 0860. PREVAIL 1: A Multiple Ascending Dose by A. Cimmino, PharmD (JK Associates Inc., a Study in Normal Healthy Volunteers of PRV- Fishawack Health Company). 3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with 0850. What Does It Mean to Be a BICLA (BILAG- Potential for Treatment of SLE Based Composite Lupus Assessment) Study Sponsor Statement: This study was Responder? Post Hoc Analysis of the Phase 3 sponsored by Provention Bio Inc TULIP-1 and TULIP-2 Trials Study Sponsor Statement: This study was 0862. Voclosporin Does Not Decrease sponsored by AstraZeneca. Mycophenolic Acid Concentrations in Patients with SLE 0851. Iberdomide Decreases B Cells and Study Sponsor Statement: The study sponsor Plasmacytoid Dendritic Cells, Increases assisted in study design, conduct, and Regulatory T Cells and IL-2, and Has Enhanced interpretation. The analyses were conducted by Clinical Efficacy in Active Systemic Lupus external experts. The presenting author assisted Erythematosus Patients with High Aiolos or the in study design and interpretation and IFN Gene Expression Signature manuscript writing. Study Sponsor Statement: This study was sponsored by Celgene, a Bristol-Myers Squibb 0863. Residual Treatment Burden, Desired Company (Princeton, NJ, USA) Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results

25 from the SLE-UPDATE (Understanding Ingelheim, Bristol-Myers Squibb, Celgene, Preferences, Disease Activity and Treatment Crescendo, Eli Lilly and Company, Genentech, Expectations) Survey in the United States Gilead, GSK, Janssen, Merck, Momenta Study Sponsor Statement: This study was Pharmaceuticals, Novartis, Pfizer Inc., sponsored by Eli Lilly and Company Regeneron, Roche, Sun, UCB, and Valeant. The design, study conduct, and financial support for 0865. Efficacy and Safety of Evobrutinib the study were provided by AbbVie. AbbVie (M2951) in Adult Patients with Systemic Lupus participated in the interpretation of data, Erythematosus Who Received Standard of Care review, and approval of the abstract. No Therapy: A Phase II, Randomized, Double-blind, honoraria or payments were made for Placebo-controlled Dose Ranging Study authorship. Study Sponsor Statement: This study was sponsored by EMD Serono Research & 0874. A Multi-Center, Randomized, Double- Development Institute, Inc., a business of Merck blind, Placebo-controlled Dose-ranging Study KGaA, Darmstadt, Germany. The study sponsor Evaluating Efficacy and Safety of SHR-1314 in was involved in the study design, collection, Subjects with Moderate-to-Severe Plaque analysis, and interpretation of data, and was Psoriasis involved in the decision to submit the abstract Study Sponsor Statement: Jiangsu Hengrui for publication. Bioscript Science provided Medicine Co., Ltd medical writing support, funded by Merck KGaA, Darmstadt, Germany. 0875. Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint 0866. Identifying an SLE Patient Cluster with Tenderness and Swelling in Patients with Greater Treatment Effect: Immune Cell Psoriatic Arthritis: 5‑Year Results from the Deconvolution of Gene Expression in Two Phase 3 FUTURE 2 Study Atacicept Phase II Studies Study Sponsor Statement: The study was Study Sponsor Statement: This study was sponsored by Novartis Pharma AG. Academic sponsored by Merck KGaA, Darmstadt, advisors and Novartis personnel designed the Germany. The study sponsor was involved in the study. Novartis conducted the data analyses. All study design, collection, analysis, and authors had access to the data and vouch for interpretation of data, and was involved in the the completeness and accuracy of the data and decision to submit the abstract for publication. analyses. Asquith D, White A, and Gaillez C are Bioscript Science provided medical writing employees of Novartis. Medical writing support support, funded by Merck KGaA, Darmstadt, was provided by Hannah Brazier and Dan Germany. Wright of OPEN Health Medical Communications, the funding for which was 0873. Impact of Skin Involvement on Disease provided by Novartis. Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic 0876. Gender Differences in Baseline Clinical Arthritis/Spondyloarthritis Registry Characteristics Among Patients with Ankylosing Study Sponsor Statement: This study was Spondylitis and Non-radiographic Axial sponsored by Corrona, LLC. Corrona has been Spondyloarthritis: Data from 3 Randomized supported through contracted subscriptions in Ixekizumab Controlled Trials the last 2 years by AbbVie, Amgen, Boehringer Study Sponsor Statement: Authors who are

26 employees of the study sponsor, Eli Lilly and provided by Costello Medical and funded by Company (Indianapolis, IN, USA), were involved UCB Pharma. in the study design, collecting and analyzing the data, interpreting the results, and preparing the 0882. Efficacy and Safety of Secukinumab in abstract. Writing support was provided by Julia Patients with Spondyloarthritis and Enthesitis Zolotarjova, MSC, MWC of Evidera/PPD and at the Achilles Tendon: 52-weeks Results from a funded by Eli Lilly and Company. Randomized, Placebo-controlled Phase 3b Trial Study Sponsor Statement: The study was 0877. Improvements in Global Functioning and sponsored by Novartis Pharma AG, Basel, Health-related Quality of Life and Their Switzerland. Academic advisors and Novartis Association with Disease Activity and Functional personnel designed the study. Statisticians Improvement in Patients with Active Ankylosing employed by Novartis conducted the data Spondylitis Treated with Upadacitinib analyses. All authors had access to the data and Study Sponsor Statement: Financial support for vouch for the completeness and accuracy of the the study was provided by AbbVie. AbbVie data and analyses. participated in interpretation of data, review, and approval of the abstract. 0883. Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying 0879. Application of Treat-to-Target in Axial Anti-Rheumatic Drugs (bDMARDs) in bDMARD- Spondyloarthritis in Daily Practice Naïve Patients with Non-Radiographic Axial Study Sponsor Statement: SpA-Net was Spondyloarthritis financially supported by grants from The Study Sponsor Statement: This study was Netherlands Organisation for Health Research funded by UCB Pharma. Editorial services were and Development (ZonMw; project number provided by Costello Medical and funded by 836042001) and Dutch Arthritis Society, and UCB Pharma. was additionally sponsored by Abbvie, Biogen, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer 0884. Comparison of Disease Control and UCB. Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic 0880. Ixekizumab Improves Signs and Arthritis/Spondyloarthritis Registry Symptoms of Patients with Radiographic and Study Sponsor Statement: This study was Non-radiographic Axial Spondyloarthritis and sponsored by Corrona, LLC. Corrona has been Extra-articular Manifestation of Enthesitis supported through contracted subscriptions in Through 16 Weeks the last 2 years by AbbVie, Amgen, Boehringer Study Sponsor Statement: Sponsored by Eli Lilly Ingelheim, Bristol-Myers Squibb, Celgene, and Company Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta 0881. Reduction of Anterior Uveitis Flares in Pharmaceuticals, Novartis, Pfizer Inc., Patients with Axial Spondyloarthritis During Regeneron, Roche, Sun, UCB and Valeant. The Treatment: 96-Week design, study conduct, and financial support for Results from the C-VIEW Study the study were provided by AbbVie. AbbVie Study Sponsor Statement: This study was participated in the interpretation of data, funded by UCB Pharma. Editorial services were review, and approval of the abstract. No

27 honoraria or payments were made for Study Sponsor Statement: This study was authorship. sponsored by Novartis Pharmaceuticals Corporation. The authors thank Karen 0885. Impact of HLA-B27 Status on Clinical Chinchilla, PhD of ArticulateScience LLC, Outcomes in Patients with Ankylosing Hamilton, NJ, USA for providing medical writing Spondylitis Treated with Secukinumab support/editorial support which was funded by Study Sponsor Statement: This study was Novartis Pharmaceuticals Corporation, East funded by Novartis Pharmaceuticals Hanover, New Jersey, in accordance with Good Corporation. The authors thank Rich Karpowicz, Publication Practice (GPP3) guidelines PhD, of Health Interactions, Inc, for providing (http://www.ismpp.org/gpp3). medical writing support/editorial support, which was funded by Novartis Pharmaceuticals 0890. Ixekizumab Treatment Improves Fatigue, Corporation, East Hanover, NJ, in accordance Spinal Pain, Stiffness, and Sleep in Patients with with Good Publication Practice (GPP3) Nonradiographic Axial Spondyloarthritis guidelines (http://www.ismpp.org/gpp3). Study Sponsor Statement: The Study was sponsored by Eli Lilly and Company. 0886. Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated 0891. Four-Year Efficacy and Safety of Patients with Ankylosing Spondylitis Guselkumab in Psoriasis Patients with and Study Sponsor Statement: AbbVie funded this Without Psoriatic Arthritis: A Pooled Analysis study and participated in the study design, from VOYAGE 1 and VOYAGE 2 research, analysis, data collection, Study Sponsor Statement: This study was interpretation of data, reviewing, and approval funded by Janssen Research & Development, of the publication. All authors had access to LLC. The sponsor facilitated the study design, relevant data and participated in the drafting, provided writing assistance and editorial review, and approval of this publication. No support for the abstract, and reviewed and honoraria or payments were made for approved the abstract prior to submission. authorship. Medical writing support was provided by M Hovenden, and J Matsuura of 0892. Long-Term Safety Profile of Ixekizumab Complete Publication Solutions, LLC and was Treatment in Patients with Axial funded by AbbVie. Spondyloarthritis Study Sponsor Statement: Eli Lilly and Company 0888. Guselkumab Efficacy and Safety in TNF- was involved in study design, collection, Inhibitor-Experienced and TNF-Inhibitor-Naïve analysis, and interpretation of data, and Patients with Active PsA: 1-Year Results of a preparation of the submitted abstract. All Phase 3, Randomized, Controlled Study authors had full access to all data in the study Study Sponsor Statement: Employees of the and had the final responsibility for the decision sponsor were involved in designing the study, to submit for publication collecting and analyzing the data, and writing and revising the abstract. 0894. Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic 0889. Efficacy of Secukinumab Treatment in Arthritis: 24-week Results from a Phase II Open Patients with Early Psoriatic Arthritis: A Pooled Label Study Analysis of 4 Phase 3 Studies

28

Study Sponsor Statement: This study is Population sponsored by AltruBio (previously AbGenomics). Study Sponsor Statement: Eli Lilly and Company funded this study 0895. Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19- 0899. Secukinumab Provides Significant Subunit of Interleukin-23, on Dactylitis and Improvement of Spinal Pain and Lowers Disease Enthesitis in Patients with Active Psoriatic Activity in Patients with Axial Spondyloarthritis: Arthritis: Pooled Results Through Week 24 from 24-week Results from a Randomized Controlled Two Phase 3 Studies Phase 3b Trial Study Sponsor Statement: This study was Study Sponsor Statement: The study was funded by Janssen Research & Development, sponsored by Novartis Pharma AG, Basel, LLC. The sponsor facilitated the study design, Switzerland. Academic advisors and Novartis provided writing assistance and editorial personnel designed the study. Statisticians support for the abstract, and reviewed and employed by Novartis conducted the data approved the abstract prior to submission. analyses. All authors had access to the data and vouch for the completeness and accuracy of the 0896. Impact of Upadacitinib on Reducing Pain data and analyses. in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with 0900. Achievement of Low Disease Activity Inadequate Response to Non-biologic or According to BASDAI with Ixekizumab in Biologic DMARDs Patients with Axial Spondyloarthritis: 16-Week Study Sponsor Statement: AbbVie funded this Results from the COAST Trials study and participated in the study design, Study Sponsor Statement: Eli Lilly and Company research, analysis, data collection, was involved in study design, collection, interpretation of data, reviewing, and approval analysis and interpretation of data, and of the publication. All authors had access to preparation of the submitted abstract. All relevant data and participated in the drafting, authors had full access to all data in the study review, and approval of this publication. No and had the final responsibility for the decision honoraria or payments were made for to submit for publication. authorship. Medical writing support was provided by M Hovenden and J Matsuura of 0901. Proinflammatory Neutrophil Function Is ICON plc (North Wales, PA) and was funded by Modulated During Secukinumab Therapy in AbbVie. Psoriatic Arthritis Without Compromising Host Defence 0897. Temporal Achievement of Clinical Study Sponsor Statement: This study was Response and Inactive Disease Status in sponsored by University of Liverpool Patients with Axial Spondyloarthritis Treated with Etanercept 0904. Response to Ixekizumab by C-reactive Study Sponsor Statement: This study was Protein Level in Patients with Radiographic sponsored by Pfizer Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF 0898. Inadequate Response Among Psoriatic Inhibitor-Experienced) Trials at 52 Weeks Arthritis Patients Prescribed Advanced Therapy Study Sponsor Statement: Eli Lilly and Company in a Real-world US Commercially Insured was involved in study design, collection,

29 analysis, and interpretation of data, and collecting and analyzing the data, and writing preparation of the submitted abstract. All and revising the abstract. authors had full access to all data in the study and had the final responsibility for the decision 0909. Residual Disease Activity in Psoriatic to submit for publication. Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or 0905. Probability of Achieving Low Disease Low Disease Activity: Results from a Phase 3b, Activity or Remission with Apremilast Randomized, Double-blinded, Active- Treatment Among DMARD-Naive Subjects with controlled, Head-to-head Study Active Psoriatic Arthritis Study Sponsor Statement: The study was Study Sponsor Statement: This study was sponsored by Novartis Pharma AG, Basel, funded by Celgene. Additional analyses were Switzerland. funded by Amgen Inc. 0910. Effect of Filgotinib on the Complete 0906. Bimekizumab Treatment Is Associated Resolution of Enthesitis in Psoriatic Arthritis with Improvements in Back Pain and Fatigue in (PsA) Patients: 52-week Results from Patients with Active Psoriatic Arthritis: 48-Week EQUATOR2 Results from a Phase 2b Study Study Sponsor Statement: EQUATOR and Study Sponsor Statement: This study was EQUATOR2 were sponsored by Galapagos NV funded by UCB Pharma. Editorial services were and co-funded by Galapagos NV and Gilead provided by Costello Medical and funded by Sciences, Inc. Medical writing support was UCB Pharma. provided by Debbie Sherwood BSc, CMPP (Aspire Scientific Ltd, Bollington, UK) and 0907. Long-term Outcomes with Filgotinib, an funded by Galapagos NV. Oral Selective Inhibitor: 100- week Data from an Open-label Extension (OLE) 0911. Impact of Filgotinib on Structural Lesions Study in Patients with Active Psoriatic Arthritis in the Sacroiliac Joints at 12 Weeks in Patients (PsA) with Active Ankylosing Spondylitis: Correlation Study Sponsor Statement: EQUATOR and with Clinical Endpoints EQUATOR2 were sponsored by Galapagos NV Study Sponsor Statement: TORTUGA was and co-funded by Galapagos NV and Gilead sponsored by Galapagos NV and co-funded by Sciences, Inc. Medical writing support was Galapagos NV and Gilead Sciences, Inc. Medical provided by Debbie Sherwood BSc, CMPP writing support was provided by Hannah Mace (Aspire Scientific Ltd, Bollington, UK) and MPharmacol, CMPP (Aspire Scientific Ltd, funded by Galapagos NV. Bollington, UK) and funded by Galapagos NV (Mechelen, Belgium). 0908. Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline 0917. Drug-Drug Interaction Study of Demographic and Disease Characteristics: Nintedanib (Ofev®) and the Combination of Pooled Results of Two Phase 3, Randomized, Ethinylestradiol and Levonorgestrel Placebo-Controlled Studies (Microgynon®) in Patients with Systemic Study Sponsor Statement: Employees of the Sclerosis-Associated Interstitial Lung Disease sponsor were involved in designing the study, (SSc-ILD) Study Sponsor Statement: Boehringer

30

Ingelheim funded this trial and was involved in provided through grants from the National its design and implementation and in the Institutes of Health (UH2-AR067676, UH2- interpretation of the data. AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2- AR067688, UH2- 0918. Decline in Forced Vital Capacity in AR067689, UH2-AR067690, UH2-AR067691, Patients with Systemic Sclerosis-Associated UH2-AR067694, UM2- AR067678, and Interstitial Lung Disease (SSc-ILD) with and AR074096). Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial 0939. Maintenance of Remission After Study Sponsor Statement: Boehringer Withdrawal of Etanercept or Methotrexate in Ingelheim funded the SENSCIS trial and was Patients with Rheumatoid Arthritis in Sustained involved in its design and implementation and Remission on Combination Therapy: Results in the interpretation of the data. from a Randomized, Double-blind, Controlled Trial 0935. Efficacy and Safety Results from a Phase Study Sponsor Statement: Study was sponsored 2, Randomized, Double-Blind Trial of BIIB059, by Amgen Inc. Linda Rice of Amgen Inc. assisted an Anti-Blood Dendritic Cell Antigen 2 in writing the abstract. Antibody, in SLE Study Sponsor Statement: This study was 0941. MDHAQ/RAPID3 (multidimensional sponsored by Biogen (Cambridge, MA, USA). Health Assessment Questionnaire/routine Writing and editorial support for the Assessment of Patient Index Data) Levels Are preparation of this abstract was provided by Elevated in Rheumatology Patients Who Meet Excel Scientific Solutions (Fairfield, CT, USA): 2011 Fibromyalgia (FM) or MDHAQ/FAST3 funding was provided by Biogen. (fibromyalgia Assessment Screening Tool) Criteria 0936. Urine Proteomics and Single Cell Study Sponsor Statement: Dr. Pincus is Transcriptomics Identify IL-16 as a Biomarker president of Medical History Services LLC, and for Lupus Nephritis holds a copyright and trademark on MDHAQ Study Sponsor Statement: This work was and RAPID3 for which he receives royalties and supported by the Accelerating Medicines license fees, all of which are used to support Partnership (AMP) Rheumatoid Arthritis and further development of quantitative Lupus Network. AMP is a public-private questionnaire measurements for patients and partnership (AbbVie Inc., Arthritis Foundation, doctors in clinical rheumatology care. Bristol-Myers Squibb Company, Lupus Foundation of America, Lupus Research 0952. Reducing Immunogenicity of Pegloticase Alliance, Merck Sharp & Dohme Corp., National (RECIPE) with Concomitant Use of Institute of Allergy and Infectious Diseases, Mycophenolate Mofetil in Patients with National Institute of Arthritis and Refractory Gout—a Phase II Double Blind Musculoskeletal and Skin Diseases, Pfizer Inc., Randomized Controlled Trial Rheumatology Research Foundation, Sanofi and Study Sponsor Statement: Funding provided by Takeda Pharmaceuticals International, Inc.) Horizon Therapeutics, PLC & National Institute created to develop new ways of identifying and of Arthritis and Musculoskeletal and Skin validating promising biological targets for Diseases (NIAMS); R21R21AR071684. diagnostics and drug development Funding was

31

0955. Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. 0986. BIIB059, a Humanized Monoclonal Results of a Randomized, Double-Blind, Antibody Targeting Blood Dendritic Cell Antigen Placebo-Controlled Phase III Trial (ProDERM 2 on Plasmacytoid Dendritic Cells, Shows Dose- Study) Related Efficacy in a Phase 2 Study in Study Sponsor Statement: This study was Participants with Active Cutaneous Lupus sponsored by Octapharma Pharmazeutika Erythematosus Produktionsges.m.b.H., Vienna Austria Study Sponsor Statement: This study was sponsored by Biogen (Cambridge, MA, USA). 0958. Tocilizumab in Myositis: Results of a Writing and editorial support for the Phase IIb Double-Blind Randomized Controlled preparation of this abstract was provided by Trial Excel Scientific Solutions (Fairfield, CT, USA): Study Sponsor Statement: This is an funding was provided by Biogen. independent investigator-initiated study which was conducted with the research grant support 0987. Efficacy and Safety of Iberdomide in from Genentech. Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, 0964. Is Meniscal Status in the Anterior Randomized, Placebo-Controlled Study Cruciate Ligament Injured Knee Associated with Study Sponsor Statement: This study was Change in Bone Surface Area? An Exploratory sponsored by Celgene, a Bristol-Myers Squibb Analysis of Data from the KANON Trial Company (Princeton, NJ, USA). Study Sponsor Statement: The KANON study and this project received funding from The 0988. Two-Year Results from a Randomized, Swedish Research Council, Greta and Johan Controlled Study of Obinutuzumab for Kock Foundations, the Medical Faculty of Lund Proliferative Lupus Nephritis University, Region Skåne, Governmental Study Sponsor Statement: This study was funding of clinical research within the national funded by F. Hoffmann-La Roche. F. Hoffmann- health services (ALF), The Swedish Rheumatism La Roche was involved in the design, execution Association, Thelma Zoegas Fund, The Stig & and reporting of the study results. Ragna Gorthon Research Foundation, Swedish National Centre for Research in Sports, Crafoord 0994. Does Tofacitinib Impact B Cell Functions? Foundation, Tore Nilsson Research Fund and Study Sponsor Statement: This work was Pfizer Global Research. The funders had no role supported by the Passerelle grant (Pfizer). in the conduct, analysis, writing or decision to submit the abstract. 1005. Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with 0985. Early and Sustained Reduction in Severity Biologic or Targeted-Synthetic DMARDs: A of Skin Disease with Anifrolumab Treatment in Multi-Database Comparative Safety Study Patients with Active SLE Measured by the Study Sponsor Statement: This study was Cutaneous Lupus Erythematosus Disease Area funded by Bristol-Myers Squibb but solely and Severity Index (CLASI): Pooled Data from 2 conducted at the Brigham and Women’s Phase 3 Studies Hospital. The funder was given the opportunity Study Sponsor Statement: This study was to make non-binding comments on a draft of sponsored by AstraZeneca. the abstract, but the authors retained the right

32 of publication and to determine the final and Biogen Samsung . The funding sources had wording. no role in the design of this study, its execution, analyses, interpretation of the data, or decision 1010. Infection and Malignancy Outcomes in to submit results Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study 1030. Pain Medication Use Among Ankylosing Study Sponsor Statement: The study was Spondylitis and Psoriatic Arthritis Patients funded by Bristol-Myers Squibb Company Before and After Initiation of Biologic Therapy Study Sponsor Statement: Eli Lilly and Company 1011. Effectiveness, Safety and Quality of Life sponsored this study. with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine 1031. Real World Treatment Patterns Among Clinical Care: First Interim Results from a Patients with Psoriatic Arthritis Treated with German Non-Interventional, Prospective, Multi- Ixekizumab Center Study Study Sponsor Statement: Scientists from Eli Study Sponsor Statement: The study ESCALATE- Lilly and Company were involved in the design, RA (ClinicalTrials.gov, NCT03387423) is funded review and interpretation of the study. by Pfizer Pharma GmbH. 1039. Tofacitinib as a Steroid-sparing Therapy 1018. Seasonal Variation in the Treat-to-Target in Pulmonary Sarcoidosis: Two Prospective Rate of Rheumatoid Arthritis (RA) and Systemic Cases and Molecular Analysis Lupus Erythematosus (SLE): A Cohort Study on Study Sponsor Statement: This is an Self-reported Data from Smart System of investigator-initiated study with expenses paid Disease Management (SSDM) by Pfizer. The pharmaceutical company played Study Sponsor Statement: Smart system of no role in the interpretation of data or the disease management (SSDM) was developed by writing of this report. Shanghai Gothic Internet Technology Co., Ltd. 1046. Risk Factors Associated with Interstitial 1027. The National Prevalence of Clinically Lung Disease in Patients with RA: Findings from Diagnosed Psoriatic Arthritis in Sweden 2017 a Retrospective Healthcare Database Analysis Study Sponsor Statement: This study was Study Sponsor Statement: This study was supported by Amgen, Eli Lilly, Novartis and sponsored by Bristol-Myers Squibb Company. Pfizer. The sponsors were allowed to comment on the study protocol, but had no influence on 1048. Reduced Decline in Forced Vital Capacity the study design and they were provided with in Patients with Progressive Fibrosing the report of the study results. Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib 1028. Probabilistic Linkage of a Cohort of Study Sponsor Statement: Boehringer Individuals with Symptoms Suggestive of Early Ingelheim funded the INBUILD trial and was Spondyloarthritis and the French National involved in its design and implementation and Healthcare Database in the interpretation of the data. Study Sponsor Statement: This study has been conducted thanks to an unrestricted grant from 1049. Effects of Nintedanib in Patients with Pfizer, Novartis, UCB , Abbvie, Merck MSD, Lilly Progressive Fibrosing Autoimmune Disease-

33 related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern 1115. The Relation of MRI-Based Cartilage Study Sponsor Statement: Boehringer Lesions to Knee Replacement and Knee Pain Ingelheim funded the INBUILD trial and was Severity in Osteoarthritis: The Multicenter involved in its design and implementation and Osteoarthritis Study in the interpretation of the data. Study Sponsor Statement: The Study Sponsor had no role in the conduct of the study. 1077. Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle 1120. A Comparison of Opioid-Related Fiber Death, and Ameliorates Muscle Weakness Outcomes Among Commercially-Insured in Experimental Polymyositis Osteoarthritis Patients Treated with Tramadol Study Sponsor Statement: This work was vs. Non-Tramadol Opioids supported by ImmunoForge, Seoul, South Study Sponsor Statement: Research funding Korea. provided by Pfizer, Inc. and Eli Lilly and Company. 1084. Consumer-based Activity Trackers in Evaluation of Physical Function in Myositis 1122. Osteoarthritis in a Large Integrated Patients Health System Population: 18-Year Study Sponsor Statement: This study was Retrospective Review funded by the Myositis Association. Study Sponsor Statement: Role of the Study Sponsor: This work was made possible at 1094. Long Term Open Label Extension of Study Geisinger by an unrestricted research grant of Tofacitinib in Refractory Dermatomyositis from Pfizer, Inc. Study Sponsor Statement: Pfizer Inc. provided research support to conduct this study 1123. The Patient Journey in Knee OA: Variations in Patient Characteristics and 1103. Metacarpo-phalangeal Osteoarthritis Is Treatment by Physician Specialty Not Rare and Is Associated with Mechanical Study Sponsor Statement: Samumed, LLC was a Rather Than Systemic Factors in Hand sponsor of the research. Drs. Bedenbaugh, Lee, Osteoarthritis: An Observational Study from a Kenndy, and Tambiah are employees of Large Hospital-based Cohort Samumed and both participated in the research Study Sponsor Statement: The DIGICOD cohort and in developing and writing the abstract. is sponsored by APHP and supported by TRB Chemedia. 1141. Reversing Seasonal Decline of T2T Outcome in RA Patients Under Double Hits by 1108. Cartilage Biomarkers s-Coll2-1 and s- Chinese New Year and COVID-19 Epidemic via Coll2-1NO2 Are Associated with Knee Online Interaction with SSDM Osteoarthritis MRI Features and Predict Disease Study Sponsor Statement: Smart system of Worsening disease management (SSDM) was developed by Study Sponsor Statement: PRODIGE study Shanghai Gothic Internet Technology Co., Ltd. (NCT02070224) was performed in the framework of a convention between the 1144. Concerns and Behaviors of Patients with Walloon region and ARTIALIS SA. (convention Common Autoimmune Rheumatic Diseases in n°6905). the United States Early in the COVID-19

34

Pandemic 1190. Sex Differences in Cardiovascular Disease Study Sponsor Statement: This project has Prevention in Patients with Rheumatoid received sponsorship support from the Patient- Arthritis: World-wide Data from the SURF-RA Centered Outcomes Institute (PCORI), Eli Lilly Study Sponsor Statement: Study was sponsored and Company, and Janssen Pharmaceutical. by Eli Lilly and Company. Eli Lilly had no role in Funders had no role in the study design, the study design, data collection and analysis, analysis, or abstract creation decision to publish or preparation of the abstract. 1153. Trends in Timing of Biologic Use for Treatment of Systemic Juvenile Idiopathic 1192. Subclinical Coronary Calcification Arthritis in the CARRA Registry Associated with Long-term Cardiovascular Study Sponsor Statement: Financial support Outcomes in Rheumatoid Arthritis provided by Genentech Study Sponsor Statement: The sponsor only provided funds for the study conduct. The 1180. External Validation of a Multi-biomarker- sponsor had no involvement in the study design, Based Cardiovascular Disease Risk Prediction data collection, processing, analysis or Score for Rheumatoid Arthritis Patients manuscript composition. Study Sponsor Statement: Myriad Genetics, Inc. provided funding for this study. 1201. Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 1181. Gains in Cardiovascular Risk Knowledge 3 Clinical Trials Through Web Based Educational Intervention Study Sponsor Statement: Funding for FINCH 1, for Rheumatoid Arthritis Patients 2, and 3 was provided by Gilead Sciences, Inc. Study Sponsor Statement: The study was Funding for this analysis was provided by Gilead funded through an Independent Educational Sciences, Inc. The sponsors participated in the Grant from Pfizer through a competitive grant planning, execution, and interpretation of the mechanism. The commercial entity did not research. participate in the conduct or reporting of the study. 1204. Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 1185. Performance of the MBDA-based CVD Randomized Controlled Trial Comparing Risk Score in RA Patient Groups of Clinical Biosimilar Infliximab-qbtx Interest (PF‑06438179/GP1111) with EU-Sourced Study Sponsor Statement: Myriad Genetics, Inc. Reference Infliximab in Patients with Active RA provided funding for this study. Study Sponsor Statement: The study sponsor monitored patient data collected by the 1189. Serum High-sensitive Cardiac Troponin at investigators for completeness and Baseline Predict Cardiovascular Events in acceptability throughout the course of the Rheumatoid Arthritis and Osteoarthritis study; generated and validated statistical Study Sponsor Statement: Pfizer research analyses; provided funding for medical writing support for cardiovascular biomarkers substudy and editorial support; and reviewed the final, for the PRECISION trial author-approved version for intellectual property protection.

35

1205. Soluble Vascular Biomarkers in Study Sponsor Statement: AbbVie funded this Rheumatoid Arthritis and Ankylosing study and participated in the study design, Spondylitis: Effects of One-year Anti-TNF-α research, analysis, data collection, Therapy interpretation of data, reviewing, and approval Study Sponsor Statement: Research grant from of the publication. All authors had access to Pfizer. relevant data and participated in the drafting, review, and approval of this publication. No 1206. Associations of Vascular and Bone Status honoraria or payments were made for in Anti-TNF-treated Rheumatoid Arthritis and authorship. Medical writing assistance was Ankylosing Spondylitis Patients provided by Frances Smith, PhD, of 2 the Nth, Study Sponsor Statement: Research grant from which was funded by AbbVie. Pfizer 1212. Whole Blood Transcriptional Changes 1207. Impact of Body Mass Index on Clinical Following Selective Inhibition of Janus Kinase 1 Responses of Novel Subcutaneous Infliximab (JAK1) by Filgotinib in MTX-Naïve Adults with (CT-P13 SC) in Patients with Active Rheumatoid Moderately-to-Severely Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase Arthritis (RA) I/III Randomized Controlled Trial Study Sponsor Statement: The sponsor (Gilead Study Sponsor Statement: This study is Sciences, Inc.), participated in the FINCH 3 trial sponsored by CELLTRION, Inc. design, and was responsible for coordinating the collection, management and analysis of the 1208. Utility of Measuring the Immunogenicity data. The academic authors and sponsor to CT-P13 for Subcutaneous Use in Patients coauthors were responsible for drafting, with Active Rheumatoid Arthritis: 1-Year editing, and revising of the abstract. Results from a Multicenter, Randomized Controlled Pivotal Trial 1213. Discrepancy Between the Multi- Study Sponsor Statement: This study is biomarker Disease Activity Score and Clinical sponsored by CELLTRION, Inc. Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection 1210. Patient-Reported Outcomes (Acthar® Gel) for Patients with Persistently Measurement Information System (PROMIS) Active Rheumatoid Arthritis Assessment of Response to Treatment with Study Sponsor Statement: The study and Golimumab IV or Infliximab in Rheumatoid editorial support for the abstract (provided by Arthritis Patients: Results from a Phase 4 Study MedLogix Communications, LLC) were funded Study Sponsor Statement: Employees of the by Mallinckrodt Pharmaceuticals. sponsor were involved in designing the study, collecting and analyzing the data, and writing 1214. Association Between Changes in C- and revising the abstract. reactive Protein at Week 12 and Patient- Reported Outcomes at Week 24 with Sarilumab 1211. Relationship Between Changes in Lipid Therapy Across Three Pivotal Phase 3 Studies Levels and Improvement in Disease Activity Study Sponsor Statement: This study was Outcomes in Patients with Rheumatoid Arthritis sponsored by Sanofi. Medical writing support Receiving Upadacitinib Treatment: Pooled for this abstract was provided by Richard Analysis of Data from Two Phase 3 Studies Hogan, PhD (Eloquent Medical Affairs, a

36 division of Envision Pharma Group), and funded by Sanofi. 1225. Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching 1215. Filgotinib Provided Rapid and Sustained Each Other If One of These Treatments Relief of Pain and Fatigue and Improved Health- Resulted in Lack of Efficacy Related Quality of Life in Patients with Study Sponsor Statement: This study was Rheumatoid Arthritis and Inadequate Response funded in part by Eli-Lilly. to Biologic DMARDs Study Sponsor Statement: Funding for FINCH 2 1226. Outcomes and Efficacy of Selective was provided by Gilead Sciences, Inc. The versus Automatic Switching from Etanercept to sponsors participated in the planning, a Biosimilar in Inflammatory Arthritis Using execution, and interpretation of the research. Electronic Health Records from UK Study Sponsor Statement: This study was 1216. Filgotinib Provided Rapid and Sustained funded by an investigated-led research grant Improvements in Functional Status, Pain, and from Biogen. The sponsor has no direct input Health Related Quality of Life, and Reduced into the acquisition and analysis of the data. Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results 1228. Baricitinib 2-mg Provides Greater from a Phase 3 Study Improvements in Patient-Reported Outcomes Study Sponsor Statement: Funding for FINCH 3 Across All Disease Activity Levels Compared to was provided by Gilead Sciences, Inc. The Placebo: Post-hoc Analyses of RA-BEACON and sponsors participated in the planning execution, RA-BUILD Trials and interpretation of the research. Study Sponsor Statement: This study was funded by Eli Lilly and Company 1218. Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, 1231. Radiographic Outcomes in Patients with Health-related Quality of Life, and Fatigue in Rheumatoid Arthritis Receiving Upadacitinib as Patients with Rheumatoid Arthritis and Monotherapy or in Combination with Inadequate Response to Methotrexate Methotrexate: Results at 2 Years Study Sponsor Statement: Gilead Sciences, Inc. Study Sponsor Statement: AbbVie sponsored The sponsors participated in the planning, the studies and contributed to their design, as execution, and interpretation of the research. well as to the analysis, collection, and interpretation of the data 1219. Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 1232. Association of Low Hemoglobin with Diabetes Improves the Glucose Homeostasis: Efficacy and Patient-reported Outcomes in Long-term Findings from TRACK Study, a Three Phase III Studies of Sarilumab (TARGET, Multicentre, Open-label, Randomised, MOBILITY and MONARCH) Controlled Trial Study Sponsor Statement: The study was Study Sponsor Statement: This study was sponsored by Sanofi (Cambridge, MA, USA) and designed as No-Profit study, according to Italian Regeneron Pharmaceuticals, Inc (Tarrytown, Law “Decreto Ministero della Salute 17 NY, USA) Dicembre 2004” to support the independent research in Italy.

37

1233. Use of Multi-Biomarker Disease Activity 1237. Pain and Other Patient-Reported Scores to Compare Biosimilar Adalimumab-afzb Outcomes in Patients with Rheumatoid Arthritis (PF-06410293) with EU-Sourced Reference Who Did or Did Not Achieve Treatment Adalimumab in a Phase 3, Randomized, Double- Response Based on Improvement in Swollen Blind Trial in Patients with Active RA Joints in Tocilizumab Clinical Trials Study Sponsor Statement: The study sponsor Study Sponsor Statement: This study was monitored patient data collected by the funded by Genentech, Inc. Genentech, Inc. was investigators for completeness and involved in the design, execution and reporting acceptability throughout the course of the of the study results. Support for third-party study; generated and validated statistical writing assistance, furnished by Health analyses; provided funding for medical writing Interactions, Inc, was provided by Genentech, and editorial support; and reviewed the final, Inc. author-approved version for intellectual property protection. 1238. Associations Between Rheumatoid Arthritis Disease Activity and Patient-reported 1234. Noninflammatory Pain Is a Frequent Outcomes in Sarilumab Clinical Trials Phenomenon in Rheumatoid Arthritis and Study Sponsor Statement: This study was Responds Well to Treatment with Sarilumab sponsored by Sanofi. Medical writing support Study Sponsor Statement: The study was for this abstract was provided by Vojislav sponsored by Sanofi (Cambridge, MA, USA) and Pejović, PhD (Eloquent Medical Affairs, a Regeneron Pharmaceuticals, Inc (Tarrytown, division of Envision Pharma Group), and funded NY, USA) by Sanofi. We acknowledge contributions of Mark C Genovese, formerly of Stanford 1235. Radiographic Progression of Structural University, who helped with interpreting these Joint Damage over 5 Years of Baricitinib data. Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND 1239. Peripheral Protein Biomarker Changes Study Sponsor Statement: This study was Following Selective Inhibition of Janus Kinase 1 funded by Eli Lilly and Company (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-Severely Active 1236. Association Between Change in Health Rheumatoid Arthritis Assessment Questionnaire Disability Index and Study Sponsor Statement: The sponsor (Gilead Treatment Response in Patients with Sciences, Inc.,) participated in the FINCH 3 trial Rheumatoid Arthritis in Tocilizumab Clinical design, and was responsible for coordinating Trials the collection, management and analysis of the Study Sponsor Statement: This study was data. The academic authors and sponsor funded by Genentech, Inc. Genentech, Inc. was coauthors were responsible for drafting, involved in the design, execution and reporting editing, and revising of the abstract. of the study results. Support for third-party writing assistance, furnished by Health 1261. Antiphospholipid Patterns Predict the Interactions, Inc, was provided by Genentech, Risk of Thrombosis in Systemic Lupus Inc. Erythematosus Study Sponsor Statement: The Hopkins Lupus

38

Cohort is funded by NIH AR 43727 and NIH AR Management (SSDM) Mobile Tools 69572. Study Sponsor Statement: Smart system of disease management (SSDM) was developed by 1262. Single LAC Positivity versus Double and Shanghai Gothic Internet Technology Co., Ltd. Triple Positivity for Thrombosis in SLE Study Sponsor Statement: The Hopkins Lupus 1303. Performance of Three Referral Cohort is funded by NIH AR 43727 and NIH AR Algorithms for Diagnosing Axial 69572 Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and 1272. Impact of Remission and Low Disease Colitis Cohort Activity Status on Hospitalizations Among SLE Study Sponsor Statement: Abbvie provided Patients from the GLADEL Latin American unrestricted funding but played no role in the Cohort conduct and reporting of the study. Study Sponsor Statement: This study was sponsored by Janssen. 1307. Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial 1275. Unexpected Changes in Physical and Spondyloarthritis with Deep Learning Psychological Measures Among Georgia Lupus Study Sponsor Statement: AbbVie Inc. funded Patients During the Early Weeks of the COVID- the study, contributed to the study design, 19 Pandemic in the United States, March 30– research, data collection. April 21, 2020 Study Sponsor Statement: The findings and 1311. Identification of Clinical Phenotypes in conclusions in this report are those of the Patients with Axial Spondyloarthritis, Peripheral authors and do not necessarily represent the Spondyloarthritis and Psoriatic Arthritis official position of the Centers for Disease According to Peripheral Musculoskeletal Control and Prevention. Manifestations: A Cluster Analysis in the International ASAS-PerSpA Study 1287. Prevalence of Morbidity Prior to Study Sponsor Statement: This study was Diagnosis of Incident Systemic Lupus conducted under the umbrella of ASAS with Erythematosus in the Danish Population unrestricted grant of Abbvie, Pfizer, Lilly, Study Sponsor Statement: The study was Novartis, UCB, Janssen and Merck. sponsored by BMS. 1314. Fatigue in Psoriatic Arthritis (PsA): 1294. Prediction of Damage in SLE Using Prevalence in Patients from the US and Europe, Unbiased Analysis of Large Datasets and Impact on Quality of Life and Work Study Sponsor Statement: The Asia Pacific Productivity Lupus Collaboration receives research support Study Sponsor Statement: This study was grants from AstraZeneca, Bristol-Myers Squibb, sponsored by Janssen. Eli Lilly, EMD Serono, GlaxoSmithKline, Janssen, and UCB Pharma. 1316. Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial 1295. Disease Activity and Mental Health in SLE Spondyloarthritis Patients: A Cross-section Study with Self- Study Sponsor Statement: This study was Assessments Based on Smart System of Disease sponsored by UCB.

39

sponsored by Novartis Pharma AG, Basel, 1319. Disease Activity and Mental Health of as Switzerland. Patients: A Cross-section Study with Self- assessments Based on Smart System of Disease 1341. Improvement in Patient-Reported Management (SSDM) Mobile Tools Outcomes in Patients with Psoriatic Arthritis Study Sponsor Statement: Smart system of with Inadequate Response to Non-Biologic disease management (SSDM) was developed by DMARDs Treated with Upadacitinib versus Shanghai Gothic Internet Technology Co., Ltd. Placebo or Adalimumab: Results from a Phase 3 Study 1322. Prevalence and Associated Factors of Study Sponsor Statement: This work/study was Sleep Disorders in Patients with Axial funded by AbbVie Inc. AbbVie participated in Spondyloarthritis. Results from the European the study design, research, data collection, Map of Axial Spondyloarthritis (EMAS) analysis and interpretation of data, writing, Study Sponsor Statement: EMAS study was reviewing, and approving the publication. All funded by Novartis Pharma AG authors had access to the data results, and participated in the development, review, and 1335. Smoking, but Not Use of Complementary approval of this abstract. No honoraria or and Alternative Medicine Predicts Residual payments were made for authorship. Functional Disability in Patients with Inflammatory Arthritis on Biologic Disease 1342. Efficacy Outcomes Following Etanercept Modifying Anti-Rheumatic Drugs: Results from Withdrawal by Sustained Remission Status in the Singapore National Biologics Register Patients with Nr-axSpA: Results from RE- Study Sponsor Statement: The Singapore EMBARK National Biologics Register is funded by the Study Sponsor Statement: This study was Chapter of Rheumatologists, College of sponsored by Pfizer. Physicians, Academy of Medicine, Singapore, which in turn receives funding from the 1343. Early Real-World Experience of manufacturers of the biologic therapies Tofacitinib for Psoriatic Arthritis: Data from a included in this study. Pharmaceutical United States Healthcare Claims Database companies providing funds to Chapter of Study Sponsor Statement: This study was Rheumatologists do not have a role in the sponsored by Pfizer Inc. Medical writing oversight of the study, data collection, data support, under the guidance of the authors, was analysis or writing of abstracts or manuscripts, provided by Gemma Turner, PhD, CMC Connect, but they do receive advance notice of McCann Health Medical Communications, and publications on which they are able to was funded by Pfizer Inc, New York, NY, USA in comment. accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 1340. Secukinumab Improves Pain, Morning 2015;163:461-464). Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients 1344. Guselkumab, an IL-23 Inhibitor That with Non-Radiographic Axial Spondyloarthritis: Specifically Binds to the IL23p19-Subunit, for Results from a Randomized Controlled Phase III Active Psoriatic Arthritis: One Year Results of a Study Phase 3, Randomized, Double-Blind, Placebo- Study Sponsor Statement: The study was Controlled Study of Patients Who Were

40

Biologic-Naïve or TNFα Inhibitor-Experien sponsor were involved in designing the study, Study Sponsor Statement: This study was collecting and analyzing the data, and writing funded by Janssen Research & Development, and revising the abstract. LLC. The Sponsor facilitated the study design, provided writing assistance and editorial 1350. Safety Profile of Upadacitinib in Psoriatic support for the abstract, and reviewed and Arthritis: Integrated Analysis from Two Phase 3 approved the abstract prior to submission. Trials Study Sponsor Statement: AbbVie and the 1345. Upadacitinib as Monotherapy and in authors thank the patients, study sites, and Combination with Non-biologic DMARDs for the investigators who participated in this clinical Treatment of Psoriatic Arthritis: Subgroup trial. AbbVie, Inc was the study sponsor, Analysis from Two Phase 3 Trials contributed to study design, data collection, Study Sponsor Statement: AbbVie and the analysis & interpretation, and to writing, authors thank the patients, study sites, and reviewing, and approval of final version. No investigators who participated in this clinical honoraria or payments were made for trial. AbbVie, Inc was the study sponsor, authorship. Medical writing support was contributed to study design, data collection, provided by Ramona Vladea, PhD of AbbVie Inc. analysis & interpretation, and to writing, reviewing, and approval of final version. No 1351. Efficacy of Ixekizumab versus honoraria or payments were made for Adalimumab in Psoriatic Arthritis (PsA) Patients authorship. Medical writing support was with and Without Moderate-to-severe provided by Ramona Vladea of AbbVie Inc. Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study 1347. Predictors of Response in Patients with Study Sponsor Statement: Eli Lilly and Company Non-Radiographic Axial Spondyloarthritis was involved in study design, collection, Receiving Certolizumab Pegol in the C-axSpAnd analysis and interpretation of data, and Study preparation of the submitted abstract. All Study Sponsor Statement: This study was authors had full access to all data in the study funded by UCB Pharma. Editorial services were and had the final responsibility for the decision provided by Costello Medical and funded by to submit for publication. UCB Pharma. 1352. Bimekizumab Maintenance of Response 1348. What Influence Do Clinical Domains in Patients with Psoriatic Arthritis: 2-Year Other Than Arthritis Have on Composite Clinical Results from a Phase 2b Dose-Ranging Study Outcomes in Psoriatic Arthritis?: Comparison of and Its Open-Label Extension Treatment Effects in the SEAM-PsA Trial Study Sponsor Statement: This study was Study Sponsor Statement: Amgen Inc funded by UCB Pharma. Editorial services were sponsored and provided funding for this study. provided by Costello Medical and funded by UCB Pharma. 1349. Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using 1353. Achievement of Remission Is Associated Composite Endpoints in Patients with Active with Improvement in Functionality in Psoriatic Arthritis Certolizumab Pegol-Treated Patients with Study Sponsor Statement: Employees of the Psoriatic Arthritis, Irrespective of Pre-Existing

41

Radiographic Structural Damage authorship. Medical writing support was Study Sponsor Statement: This study was provided by Ramona Vladea, PhD of AbbVie Inc. funded by UCB Pharma. Editorial services were provided by Costello Medical and funded by 1358. Certolizumab Pegol Efficacy in Patients UCB Pharma. with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive 1354. The Effect of 8 Years of TNF-α Blocking Protein Status Therapy on Bone Mineral Density in Patients Study Sponsor Statement: This study was with Ankylosing Spondylitis funded by UCB Pharma. Editorial services were Study Sponsor Statement: The GLAS cohort was provided by Costello Medical and funded by supported by unrestricted grants from Pfizer, UCB Pharma. Abbvie, UCB and Novartis. These pharmaceutical companies had no role in the 1359. Targeted Serum Proteomic Analysis design, conduct, interpretation, or publication Following Upadacitinib Treatment in Ankylosing of this study. Spondylitis Shows Robust Suppression of Innate and Adaptive Immune Pathways with Tissue 1355. Characterization of Remission in Patients Repair Modulation with Psoriatic Arthritis Treated with Study Sponsor Statement: AbbVie, Inc was the Upadacitinib: Post-hoc Analysis from Two Phase study sponsor, contributed to the study design, 3 Trials data collection, analysis & interpretation, and Study Sponsor Statement: AbbVie and the to writing, reviewing, and approval of the final authors thank the patients, study sites, and version. investigators who participated in this clinical trial. AbbVie, Inc was the study sponsor, 1361. Secukinumab Significantly Decreased contributed to study design, data collection, Joint Synovitis Measured by Power Doppler analysis & interpretation, and to writing, Ultrasonography in Biologic-naïve Patients with reviewing, and approval of final version. No Active Psoriatic Arthritis: Primary (12-Week) honoraria or payments were made for Results from a Randomized, Placebo-Controlled authorship. Medical writing support was Phase III Study provided by Ramona Vladea, PhD of AbbVie Inc. Study Sponsor Statement: The study was sponsored by Novartis Pharma AG, Basel, 1356. Efficacy of Upadacitinib in Patients with Switzerland. Academic advisors and Novartis Psoriatic Arthritis Stratified by Number of Prior personnel designed the study. Statisticians Biologic Disease-modifying Anti-rheumatic employed by Novartis conducted the data Drugs analyses. All authors had access to the data and Study Sponsor Statement: AbbVie and the vouch for the completeness and accuracy of the authors thank the patients, study sites, and data and analyses. investigators who participated in this clinical trial. AbbVie, Inc was the study sponsor, 1363. Efficacy of Secukinumab on Patient- contributed to study design, data collection, Reported Outcomes in Patients with Active analysis & interpretation, and to writing, Psoriatic Arthritis Stratified by Prior Tumor reviewing, and approval of final version. No Necrosis Factor Inhibitor Use: Post Hoc Analysis honoraria or payments were made for from a Phase 3 Trial Study Sponsor Statement: This study was

42 sponsored by Novartis Pharmaceuticals analyses. All authors had access to the data and Corporation, East Hanover, NJ. Novartis vouch for the completeness and accuracy of the participated in the study design, interpretation data and analyses. of data, and review and approval of this abstract. Support for third-party writing 1367. Impact of Ixekizumab on Work assistance for this abstract, furnished by Productivity in Non-Radiographic Axial Elizabeth Ohneck, PhD, of Health Interactions, Spondyloarthritis Patients: Results from the Inc, was provided by Novartis Pharmaceuticals COAST-X Trial at 52 Weeks Corporation, East Hanover, NJ. Study Sponsor Statement: The Study was sponsored by Eli Lilly and Company. 1364. Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with 1368. Proportions of Patients Achieving a Ankylosing Spondylitis: Interim Results from a Minimal Disease Activity State upon Treatment Phase 2b Open-Label Extension Study with in a Psoriatic Arthritis Phase Study Sponsor Statement: This study was 2b Study funded by UCB Pharma. Editorial services were Study Sponsor Statement: Studies were funded provided by Costello Medical and funded by by Merck Sharp & Dohme Corp; analyses by Sun UCB Pharma. Pharmaceutical Industries, Inc.

1365. Machine Learning-based Berlin Scoring of 1369. Efficacy of Tildrakizumab in PsA: DAPSA Magnetic Resonance Images of the Spine in Remission and Low Disease Activity in PASDAS Patients with Ankylosing Spondylitis: Analysis of Through Week 52 Data from a Phase 3 Trial with Secukinumab Study Sponsor Statement: Studies were funded Study Sponsor Statement: The study was by Merck Sharp & Dohme Corp; analyses by Sun sponsored by Novartis Pharma AG. Academic Pharmaceutical Industries, Inc. advisors from Oxford Big Data Institute (BDI) and Novartis personnel designed the project. 1370. A Delayed Effect of Tumor Necrosis The Oxford BDI – Cosentyx Collaboration group Factor Inhibitors on Radiographic Spinal conducted the data analyses, and all authors Progression in Patients with Axial had access to the data and, to the best of their Spondyloarthritis: Long-term Results from the knowledge, confirm the accuracy and German Spondyloarthritis Inception Cohort completeness of the analyses. Study Sponsor Statement: GESPIC was initially supported by the German Federal Ministry of 1366. Secukinumab Improved Signs and Education and Research (Bundesministerium für Symptoms in Patients with Non-radiographic Bildung und Forschung—BMBF). As Axial Spondyloarthritis: Results from a consequence of the funding reduction by BMBF Randomized Controlled Phase III Study according to schedule in 2005 and stopped in Stratified by Baseline Objective Signs of 2007, complementary financial support has Inflammation been obtained also from Abbott, Amgen, Study Sponsor Statement: The study was Centocor, Schering–Plough, and Wyeth. Starting sponsored by Novartis Pharma AG, Basel, from 2010, the core GESPIC cohort was Switzerland. Academic advisors and Novartis supported by AbbVie. personnel designed the study. Statisticians employed by Novartis conducted the data

43

1371. Improvement in Patient-Reported 1378. Understanding Diagnostic Pathways in Outcomes for Upadacitinib versus Placebo Systemic Sclerosis and Systemic Sclerosis- Among Patients with Psoriatic Arthritis and an Associated Interstitial Lung Disease (SSc-ILD) Inadequate Response to Biologic Disease- Study Sponsor Statement: The sponsor of this Modifying Anti-Rheumatic Drugs study, Boehringer Ingelheim Pharmaceuticals, Study Sponsor Statement: This work/study was contributed to the design, analysis, data funded by AbbVie Inc. AbbVie participated in interpretation, and preparation of the abstract. the study design, research, data collection, analysis and interpretation of data, writing, 1379. Clinical Outcomes Among Participants reviewing, and approving the publication. All with Diffuse Systemic Sclerosis Contracting authors had access to the data results, and COVID-19 During Clinical Studies of Lenabasum: participated in the development, review, and A Case Series approval of this abstract. No honoraria or Study Sponsor Statement: Support for the payments were made for authorship. study and abstract submission was provided by Corbus Pharmaceuticals, Norwood, MA 1372. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial 1381. Real-World Mono-, Double and Triple Involvement Combination Treatment Patterns with Study Sponsor Statement: AbbVie funded this Macitentan in Patients with Pulmonary Arterial study and participated in the study design, Hypertension Associated with Connective research, analysis, data collection, Tissue Disease (PAH-CTD): Evidence from the interpretation of data, reviewing, and approval Combined OPUS/OrPHeUS Dataset of the publication. All authors had access to Study Sponsor Statement: The OPUS Registry relevant data and participated in the drafting, and the OrPHeUS medical chart review are review, and approval of this publication. No sponsored by Actelion Pharmaceuticals Ltd. The honoraria or payments were made for Sponsor participated in the conception and authorship. Medical writing support was design of the analysis and interpretation of the provided by M Mehta, and J Matsuura of ICON data, drafting and critical revision of the report, plc (North Wales, PA) and was funded by and approved submission of the manuscript. AbbVie. 1382. Changes in Imaging Markers in Patients 1374. Secukinumab in the Treatment of with Systemic Sclerosis-Associated Interstitial Dactylitis in Patients with Psoriatic Arthritis: Lung Disease (SSc-ILD) Treated with Nintedanib: Post Hoc Analysis Results from a Randomized Sub-Study of the SENSCIS Trial Phase 3 Trial Study Sponsor Statement: Boehringer Study Sponsor Statement: The study was Ingelheim funded the SENSCIS trial and was sponsored by Novartis Pharma AG, Basel, involved in its design and implementation and Switzerland. Academic advisors and Novartis in the interpretation of the data personnel designed the study. Statisticians employed by Novartis conducted the data 1400. cAMP Response Element Modulator analyses. All authors had access to the data and (CREM)α Promotes PD-1- effector CD4+ T Cells vouch for the completeness and accuracy of the in Psoriasis and Psoriatic Arthritis data and analyses. Study Sponsor Statement: This study was

44 supported by Novartis Pharmaceutical through 1464. Multi-Variate Approach Including a non-restricted funding call. Serology and Genetics for an Improved Identification of Patients at Risk of Developing 1428. The Efficacy and Safety of Tocilizumab in Rheumatoid Arthritis Patients with Giant Cell Arteritis: A Systematic Study Sponsor Statement: Some of the Review and Meta-Analysis biomarkers where performed without payment Study Sponsor Statement: This study was by Phadia/Thermofisher . No financial support funded by Genentech, Inc. Genentech, Inc. was has been received by the academic authors for involved in the design, execution and reporting this work. of the study results. Support for third-party writing assistance, furnished by Health 1479. Long-Term Effectiveness of Interactions, Inc., was provided by Genentech, in Autoinflammatory Diseases – Interim Inc. Analysis of the CAPS Subgroup from the RELIANCE Registry 1441. Effects of Belimumab on Renal Study Sponsor Statement: This abstract was Outcomes, Overall SLE Control and Biomarkers: sponsored by Novartis Pharma, who is the Findings from a Phase 3, Randomized, Placebo- sponsor of the RELIANCE registry for real world controlled 104-week Study in Patients with evidence of canakinumab rare Active Lupus Nephritis autoinflammatory conditions, the abstract is Study Sponsor Statement: Study Funding: GSK based on.

1444. Cluster-randomized Pragmatic Clinical 1480. Abatacept for the Treatment of IgG4- Trial Evaluating the Potential Benefit of a Tight- Related Disease control and Treat-to-target Strategy in Axial Study Sponsor Statement: This is an Spondyloarthritis: The Results of the TICOSPA investigator-initiated trial funded by Bristol- Trial Myers Squibb (BMS). Study Sponsor Statement: UCB provided an unrestricted grant for this study, and had no 1482. Joint Safety with Tanezumab: Integrated role on providing any drug, nor in the study Analyses from Randomized Controlled Phase 3 design, data collection, data analysis, data Studies in Patients with Osteoarthritis interpretation, or writing of the report. Study Sponsor Statement: Funded by Pfizer and Eli Lilly and Company 1460. “Can I Help You with Your RA Today?”: A Pilot Study on the User Experience with a 1485. LNA043, a Novel Cartilage Regenerative Voice-Enabled Smartphone App to Virtually Treatment for Osteoarthritis: Results from a Monitor Disease Activity and Collect ePROs in First-In-Human Trial in Patients with Knee Rheumatoid Arthritis Osteoarthritis Study Sponsor Statement: Janssen Research & Study Sponsor Statement: This study was Development sponsored the study and two sponsored by Novartis. authors are Janssen employees. They had input on the design of the study and approved of the 1486. Long-term Efficacy and Safety of Intra- abstract. They did not restrict the academic articular Sprifermin in Patients with Knee authors in any specific manner. Osteoarthritis: Results from the 5-Year Forward Study

45

Study Sponsor Statement: This study was Partnership (AMP) Rheumatoid Arthritis and sponsored by Merck KGaA, Darmstadt, Lupus Network. AMP is a public-private Germany. The study sponsor was involved in the partnership (AbbVie Inc., Arthritis Foundation, study design, collection, analysis, and Bristol-Myers Squibb Company, Lupus interpretation of data, and was involved in the Foundation of America, Lupus Research decision to submit the abstract for publication. Alliance, Merck Sharp & Dohme Corp., National Bioscript Science provided medical writing Institute of Allergy and Infectious Diseases, support, funded by Merck KGaA, Darmstadt, National Institute of Arthritis and Germany. Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and 1493. Distinct Patient-level Patterns of Takeda Pharmaceuticals International, Inc.) Response to Methotrexate in Juvenile created to develop new ways of identifying and Idiopathic Arthritis validating promising biological targets for Study Sponsor Statement: The CLUSTER diagnostics and drug development Funding was consortium has been provided generous grants provided through grants from the National from AbbVie, Sobi and Pfizer. Institutes of Health (UH2-AR067676, UH2- The funders including those listed above had no AR067677, UH2-AR067679, UH2-AR067681, role in study design, collection, analysis or UH2-AR067685, UH2- AR067688, UH2- interpretation of data or preparation of this AR067689, UH2-AR067690, UH2-AR067691, abstract. SSW had full access to all data in the UH2-AR067694, UM2- AR067678, and study and had final responsibility for the AR074096). decision to submit this abstract. 1513. Role of Platelet C4d in Thrombosis and 1495. Tofacitinib for the Treatment of Patients Lupus Nephritis with Juvenile Idiopathic Arthritis: An Interim Study Sponsor Statement: Exagen Diagnostics Analysis of Data up to 5.5 Years from an Open- paid for the Platelet C4d assays. label, Long-term Extension Study Study Sponsor Statement: This study was 1515. Renal Responder Status and Associated sponsored by Pfizer Inc. Medical writing Clinical Variables in the Lupus Accelerating support, under the guidance of the authors, was Medicines Partnership Cohort provided by Gemma Turner, PhD, CMC Connect, Study Sponsor Statement: The Accelerating McCann Health Medical Communications, and Medicines Partnership is funded by a public- was funded by Pfizer Inc, New York, NY, USA in private collaboration between the NIH, industry accordance with Good Publication Practice and foundations (including the Rheumatology (GPP3) guidelines (Ann Intern Med Research Foundation). 2015;163:461-464). 1516. The Value of Renal Biopsy at Lower Levels 1512. Trajectory Analysis of Repeat Renal of Proteinuria in Patients Enrolled in the Lupus Biopsies Identified Previous Endocapillary Accelerating Medicines Partnership Proliferation as Predictor of Damage and End Study Sponsor Statement: The Accelerating Stage Renal Disease in Pure Membranous Lupus Medicines Partnership is funded by a public- Nephritis private collaboration between the NIH, industry Study Sponsor Statement: This work was and foundations (including the Rheumatology supported by the Accelerating Medicines Research Foundation).

46

Study Sponsor Statement: Pfizer, Inc provided 1518. The Role for Neutrophils in the Early the funding support for the quality Phases of Enthesitis in Spondyloarthritis improvement initiative. Pfizer, Inc has not had Study Sponsor Statement: This work was any involvement in the creation, development, supported by a grant provided by AbbVie, Inc.. or conduct of this project, or reporting of project results. 1527. Tofacitinib Inhibits Angiogenesis Through Its Opposite Effects on Pro- and Anti-angiogenic 1624. Improving Pneumococcal Vaccination in Factors Veterans with Rheumatic Diseases Study Sponsor Statement: The study was Study Sponsor Statement: The study sponsor funded by an Investigator Initiative Study Grant had no role in the design, execution, analysis, from Pfizer pharmaceutics. The funding source interpretation of the data, or decision to submit had no role in the design of this study and did results of this study. not have any role during its execution, analyses, interpretation of the data, or decision to submit 1630. Long-term Safety of Tildrakizumab in results. Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major 1544. Tc99m Tilmanocept Imaging Is an Early Adverse Cardiovascular Events Through 3 Years Predictor of Clinical Response in Rheumatoid (148 Weeks) from Two Phase 3 Trials Arthritis Patients Beginning New Anti-TNFα Study Sponsor Statement: Studies were funded Therapy by Merck Sharp & Dohme Corp; analyses by Sun Study Sponsor Statement: This clinical trial is Pharmaceutical Industries, Inc. sponsored and paid for by Navidea Biopharmaceuticals. 1631. No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc 1550. Change in Tophus Size Measured with Analyses of the Tildrakizumab Psoriasis Clinical Dual-energy CT and Ultrasound: A 1-year Program Multicenter Follow-up Study Study Sponsor Statement: Studies were funded Study Sponsor Statement: This was an by Merck Sharp & Dohme Corp; analyses by Sun investigator initiated study sponsored by Pharmaceutical Industries, Inc. Horizon Pharmaceuticals 1632. Long-Term Efficacy and Safety of 1562. Subclinical Joint Inflammation of Hands Canakinumab in Patients with by Magnetic Resonance Imaging in Patients Autoinflammatory Periodic Fever Syndromes – with Psoriatic Arthritis in Clinical Remission First Interim Analysis of the FMF-TRAPS- Compared to Active Disease HIDS/MKD Subgroup of the RELIANCE Registry Study Sponsor Statement: Janssen has Study Sponsor Statement: Novartis is sponsor participated the design of the study and of the Reliance registry study. Reliance is sponsored the cost of the MRI tests. collecting real world data for hereditary recurrent fever conditions treated with 1623. Improving Pneumococcal Vaccination canakinumab in clinical routine. Rates Among Immunosuppressed Adults in an Academic Rheumatology Clinic Utilizing a Nurse 1633. A Randomized, Double-Blind, Placebo- Driven Protocol Controlled Study of Anakinra in Pediatric and

47

Adult Patients with Still’s Disease Study Sponsor Statement: This study was Study Sponsor Statement: This study was fully supported by Corbus Pharmaceuticals, Inc. funded by Swedish Orphan Biovitrum AB (publ) 1640. Clinically Important Improvement in 1635. Profile of Topical Diclofenac Sodium Gel Osteoarthritis Pain at Week 16 After 1% (Voltaren®) Users in a United States Subcutaneous Administration of Tanezumab: Longitudinal Electronic Health Records Pooled Analysis from International Studies Database Study Sponsor Statement: The studies were Study Sponsor Statement: The sponsor, GSK sponsored by Pfizer and Eli Lilly and Company. Consumer Healthcare, Warren, New Jersey, US Medical writing support was provided by Kim participated in the study design, as well as data Russell, PhD, of Engage Scientific Solutions collection, analysis, and interpretation. The (Horsham, UK) and was funded by Pfizer and Eli Sponsor also provided funding for medical Lilly and Company. writing support and participated in the decision to submit the manuscript for publication. 1641. Clinically Important Improvements in Jess D. Edison is a military service member. This Patients with Osteoarthritis Treated with work was prepared as part of his official duties. Subcutaneous Tanezumab: Results from a 56- Title 17 U.S.C. 105 provides that “Copyright Week Randomized NSAID-Controlled Study protection under this title is not available for Study Sponsor Statement: Sponsored by Pfizer any work of the United States Government.” and Eli Lilly & Company. Medical writing Title 17 U.S.C. 101 defines a United States support was provided by Jacqui Oliver PhD, of Government work as a work prepared by a Engage Scientific Solutions and was funded by military service member or employee of the Pfizer and Eli Lilly & Company. United States Government as part of their official duties. The identification of specific 1642. Observed Efficacy with Subcutaneous products or scientific instrumentation is Tanezumab Is Early and Maintained in Patients considered an integral part of the scientific with Osteoarthritis: Results from a 56-Week endeavor and does not constitute endorsement Randomized NSAID-Controlled Study or implied endorsement on the part of the Study Sponsor Statement: The study was author, DoD, or any component agency. The sponsored by Pfizer and Eli Lilly & Company. views expressed in this presentation are those Medical writing support was provided by Jacqui of the authors and do not reflect the official Oliver PhD, of Engage Scientific Solutions and policy of the Department of Army/Navy/Air was funded by Pfizer and Eli Lilly & Company. Force, Department of Defense, or U.S. Government. Research data was derived with 1643. Evaluating Analgesic Response to oversight from Naval Medical Center, Subcutaneous Tanezumab in Patients with Portsmouth, Virginia IRB, NHRS identifier; Inadequate Treatment Response to Other number NMCP.2017.0096. Analgesics Based on Daily E-pain Diaries: A Pooled Analysis of 2 Randomized, Placebo- 1639. Preliminary Baseline Subject controlled Studies Demographics and Disease Characteristics in a Study Sponsor Statement: The study was Phase 3 Clinical Trial of the Safety and Efficacy sponsored by Pfizer and Eli Lilly and Company. of Lenabasum in Dermatomyositis (DETERMINE)

48

1644. Radiographic Exclusionary Findings Arthritis, Musculoskeletal and Skin Diseases (PI: During Screening for Three Phase III Trials of Yu, CY) Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis 1696. Measuring Quality Improvement from Study Sponsor Statement: Studies were CME Participants: Results from the RAPID® CME sponsored by Pfizer and Eli Lilly and Company. Initiative Study Sponsor Statement: Role of the Study 1645. Placebo Group Responses in Clinical Trials Sponsor: The RAPID initiative and analysis of of Patients with Osteoarthritis: Data from the RAPID data were supported through Tanezumab Development Program independent educational grants from AbbVie Study Sponsor Statement: These studies were and Sanofi Genzyme and Regeneron. sponsored by Pfizer and Lilly. 1702. RA-Related Knowledge and Skills of 1646. Use of Prescription Nonsteroidal Anti- Rheumatology Fellows Among 20 US Academic inflammatory Drugs (NSAIDs) in Adults with Institutions Hip/Knee Osteoarthritis (OA) at Increased Risk Study Sponsor Statement: The study reported for NSAID-related Adverse Events in this abstract was funded by an independent Study Sponsor Statement: Role of the Study educational grant from Gilead Sciences, Inc. The Sponsors: This research was funded by grantors had no role in the study design, Regeneron Pharmaceuticals Inc and Teva execution, analysis, or reporting. Pharmaceutical Industries Ltd. 1707. Development and Delivery of Continuing 1647. An Oleuropein-based Dietary Supplement Education Interventions Promoting Shared Improves Joint Function in Older People with Decision Making in Rheumatoid Arthritis High Knee Joint Pain Study Sponsor Statement: This study was in Study Sponsor Statement: Nestle, NHS, part funded by an unrestricted educational Lausanne, Switzerland grant from Eli Lilly.

1656. Knee OA Outcomes in Patients with 1713. Exploring Novel Tenosynovitis and Severe Obesity Following Bariatric Surgery or Combined Inflammation Imaging Outcomes: Total Knee Arthroplasty Results from a Randomized Controlled Trial in Study Sponsor Statement: This study was Early Rheumatoid Arthritis supported by the Investigator Initiated Study Study Sponsor Statement: This study was Program of Ethicon-Endo Surgery, Inc. (Grant sponsored by Pfizer Inc. Medical writing Number: 14-621). support, under the guidance of the authors, was provided by Jennifer Arnold, PhD, CMC Connect, 1670. Low Copy Number of Long C4 Genes Is a McCann Health Medical Communications, and Genetic Risk Factor for Childhood Onset SLE was funded by Pfizer Inc, New York, NY, USA in (cSLE) but Is Associated with Higher Age of accordance with Good Publication Practice Disease Onset (GPP3) guidelines (Ann Intern Med Study Sponsor Statement: Collaboration 2015;163:461-464). between the co-authors would not have been possible without the financial support from NIH 1714. Disease Activity Trajectories for Early and grant R01 AR073311, National Institute of Established Rheumatoid Arthritis: Real World

49

Results from a Rheumatoid Arthritis Cohort Study Sponsor Statement: This project was Study Sponsor Statement: OBRI was funded by supported by Janssen Research and peer reviewed grants from CIHR (Canadian Development through an investigator-initiated Institute for Health Research), Ontario Ministry grant. of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and 1723. RA Flare Prediction via Machine Learning unrestricted grants from: Abbvie, Amgen, and Algorithm Based on SSDM Big Data Janssen, Medexus, Merck, Novartis, and Pfizer. Study Sponsor Statement: Smart system of Acknowledgment: Dr. Bombardier held a disease management (SSDM) was developed by Canada Research Chair in Knowledge Transfer Shanghai Gothic Internet Technology Co., Ltd. for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology 1728. Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with 1715. Longitudinal Patterns of Remission in Rheumatoid Arthritis and an Inadequate Real-World Early Rheumatoid Arthritis Patients: Response to Biologic Disease-Modifying Results from the Canadian Early Arthritis Cohort Antirheumatic Drugs: 12-Week Results of a (CATCH) Phase 3 Study Study Sponsor Statement: The CATCH study Study Sponsor Statement: This work/study was was designed and implemented by the funded by AbbVie Inc. AbbVie participated in investigators and financially supported through the study design, research, data collection, unrestricted research grants from: Amgen and analysis and interpretation of data, writing, Pfizer Canada - Founding sponsors since reviewing, and approving the publication. All January 2007; AbbVie Corporation and authors had access to the data results, and Hoffmann-LaRoche since 2011; Medexus Inc. participated in the development, review, and since 2013; Eli Lilly Canada since 2016, Merck approval of this abstract. No honoraria or Canada since 2017, Sandoz Canada, payments were made for authorship. Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded 1729. Associations Between Patient Reported by Janssen Biotech from 2011-2016, UCB Outcomes and Impairments of Work and Canada and Bristol-Myers Squibb Canada from Activity in Patients with Rheumatoid Arthritis 2011-2018, and Sanofi Genzyme from 2016- Who Achieved Clinical Remission; Retrospective 2017. Analysis Using the IORRA Database Study Sponsor Statement: The role of the study 1719. Prevalence and Trajectory of Erosions, sponsor is contribution to the study conception Synovitis, and Bone Marrow Edema in Feet of and design. Patients with Early Rheumatoid Arthritis Study Sponsor Statement: The project is an 1730. Comparison of MBDA Score, Patient investigator-initiated study by Dr. Maggie Global Assessment and Evaluator Global Larché with funding by AbbVie Inc (Grant Assessment for Predicting Risk of Radiographic number IMM-12-0084). Progression Study Sponsor Statement: Myriad Genetics, Inc. 1720. Factors Associated with an Increased Risk provided funding for this study. of Imminent Rheumatoid Arthritis in ACPA+ Individuals

50

1732. Machine Learning Coupled with Patient SPRL Brussels, Belgium provided in the context Reported Outcome Data to Classify & Predict of an Investigator initiated trial RA Disease Activity Study Sponsor Statement: This study was 1758. Prevalence and Incidence of Infection sponsored by Janssen Pharmaceutical and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various 1738. Promote Treat-to-Target for RA via DMARD Classes: Real-World Analysis of 2012– Empowering Patients: A Cohort Study from 2016 US Medicare Data China by Smart System of Disease Management Study Sponsor Statement: Gilead Sciences, Inc. (SSDM) financially supported the study and participated Study Sponsor Statement: Smart system of in the planning, execution, and interpretation of disease management (SSDM) was developed by the research. Shanghai Gothic Internet Technology Co., Ltd. 1762. Benefit and Risk Profiles of Janus Kinase 1745. A Novel Method for Predicting 1-Year Inhibitors Approved in the US for the Retention of Abatacept Using Machine Learning Treatment of RA Techniques Study Sponsor Statement: This abstract was Study Sponsor Statement: The study was sponsored by Eli Lilly and Company, under funded by Bristol-Myers Squibb Company license from Incyte Corporation.

1747. Brain fMRI Predicts Responses to 1763. Blending Hierarchical Cluster Analysis and Certolizumab Pegol in RA. an International, Cluster-Specific Regressions to Predict Clinical Multi-center, Randomized, Double-blind, Outcome to Tofacitinib Treatment in Patients Placebo-controlled Trial (PreCePRA) with Rheumatoid Arthritis Study Sponsor Statement: Study was sponsored Study Sponsor Statement: This study was by an unrestricted grant of UCB Biopharma sponsored by Pfizer Inc. Medical writing SPRL Brussels, Belgium provided in the context support, under the guidance of the authors, was of an Investigator initiated trial. provided by Emma Deeks, PhD, CMC Connect, McCann Health Medical Communications, and 1749. Efficacy of Filgotinib in Patients with was funded by Pfizer Inc, New York, NY, USA in Rheumatoid Arthritis with Poor Prognostic accordance with Good Publication Practice Factors: Post Hoc Analysis (GPP3) guidelines (Ann Intern Med Study Sponsor Statement: Funding for FINCH 3 2015;163:461-464). was provided by Gilead Sciences, Inc. The sponsors participated in the planning, 1793. Safety of Obtaining Research Tissue execution, and interpretation of the research. During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines 1750. Longitudinal Change in the Central Partnership Nervous System Pain Response After Treatment Study Sponsor Statement: The Accelerating with Certolizumab or Placebo. a Post-hoc Medicines Partnership is funded by a public- Analysis from the Pre-CEPRA Trial private collaboration between the NIH, industry Study Sponsor Statement: Study was sponsored and foundations (including the Rheumatology by an unrestricted grant of UCB Biopharma Research Foundation).

51

1797. A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement 1824. Selective Expansion of Regulatory T Cells Activation Products (CB-CAPs) Is Superior to in Patients with Systemic Lupus Erythematosus Anti-dsDNA and Low Serum Complement Levels by a Novel IL-2 Conjugate, NKTR-358 in Predicting Transition of Probable Lupus to Study Sponsor Statement: This study was ACR Classified Lupus Within 2 Years sponsored by Nektar Therapeutics. Study Sponsor Statement: This work was funded by Exagen Inc. 1826. •Maintenance of Efficacy and Safety and Reduction of BILAG Flares with Ustekinumab, 1803. Ability of Innate, Adaptive, and TNF- an Interleukin-12/23 Inhibitor, in Patients with Superfamily Immune Pathways to Characterize Active Systemic Lupus Erythematosus: 2-Year Disease Activity and Inform a Refined Lupus Results of a Phase 2, Randomized Placebo- Disease Activity Immune in a Confirmatory Controlled, Crossover Study Cohort of SLE Patients Study Sponsor Statement: Employees of the Study Sponsor Statement: This study was sponsor were involved in designing the study, sponsored in part by Progentec Diagnostics, collecting and analyzing the data, and writing Inc., providing salary, experimental resources and revising the abstract. (equipment and supplies), and technical support. 1827. Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with 1808. Erythrocyte Complement Receptor 1 Anifrolumab in 2 Phase 3 Trials (ECR1) and Erythrocyte Bound C4d (EC4d) Study Sponsor Statement: This study was Associate with Adverse Pregnancy Outcomes sponsored by AstraZeneca. and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE) 1828. Comprehensive Efficacy of Anifrolumab Study Sponsor Statement: This work was Across Organ Domains in Patients with Active funded by Exagen Inc. SLE: Pooled Data from 2 Phase 3 Trials Study Sponsor Statement: This study was 1819. Altered Brain Functional Connectivity in sponsored by AstraZeneca. Systemic Lupus Erythematosus Study Sponsor Statement: This study was 1829. Lupus Disease Activity After Cessation of partially funded by an unrestricted grant from Anifrolumab Treatment During the Phase 2b Sanofi Genzyme. Sanofi Genzyme was not MUSE Trial Follow-up Period involved in the conduct or analysis of the study. Study Sponsor Statement: This study was The abstract was sent to them prior to sponsored by AstraZeneca. submission to ACR for comments. 1831. Biomarkers Linked to Anti-IFN-I and 1822. Serum Proteomics from a Phase III, Ustekinumab Suggest Distinct Mechanism of Randomized, Placebo-Controlled Study of Action in Systemic Lupus Erythematosus Patients with Active Lupus Nephritis: Study Sponsor Statement: Employees of the Correlation with Baseline Disease sponsor were involved in designing the study, Characteristics and Response to Therapy collecting and analyzing the data, and writing Study Sponsor Statement: This study was and revising the abstract. sponsored by Bristol-Myers Squibb Company

52

1834. Biomarker Analysis of IFN-I Modulation in Proteinurea Reduction in the Presence of Low- JNJ-839: First-in-Human Study for Systemic Dose Steroids Lupus Erythematosus Study Sponsor Statement: This study was Study Sponsor Statement: Employees of the funded by Aurinia Pharmaceuticals, Inc. sponsor were involved in designing the study, collecting and analyzing the data, and writing 1847. Delayed and Immediate Release and revising the abstract. Prednisone Decrease Fatigue Comparably in Patients with Systemic Lupus Erythematosus 1836. Alternative Renal Response Definitions in Study Sponsor Statement: This study was a Randomized, Controlled Trial of supported by a grant from Horizon Obinutuzumab for Proliferative Lupus Nephritis Therapeutics. Study Sponsor Statement: This study was funded by F. Hoffmann-La Roche. F. Hoffmann- 1864. How to Diagnose Axial Spondyloarthritis La Roche was involved in the design, execution in 2020? A Data-Driven Estimation of the and reporting of the study results. Disease Probability in Patients with a priori Different Likelihoods of the Diagnosis 1837. Clinical Outcomes in Lupus Nephritis by Study Sponsor Statement: The OptiRef study Renal Response Status: A Retrospective was supported by an unrestricted research Analysis of the Hopkins Lupus Cohort grant from Novartis. Study Sponsor Statement: GSK. The Hopkins Lupus Cohort is funded by NIH grant R01- 1865. Identification of Parameters Associated AR069572. with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European 1840. A Novel Biomarker Identifies Systemic Map of Axial Spondyloarthritis (EMAS) Lupus Erythematous (SLE) Patients Who Benefit Study Sponsor Statement: EMAS was funded by from Obexelimab (XmAb®5871) Treatment Novartis Pharma AG Study Sponsor Statement: The clinical study was funded by Xencor and the biomarker work 1866. Patient-reported Impact of Axial was performed by OMRF with funding from Spondyloarthritis on Working Life. Results from Xencor. the Spanish Atlas 2017 Study Sponsor Statement: Atlas 2017 study 1842. Repository Corticotropin Injection was funded by Novartis Farmacéutica Spain (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of 1869. “Rheum to Diagnosis”: Uncovering Patient-Reported Outcomes from a Phase 4, Impediments to Accurate Diagnosis of Non- Multicenter, Randomized, Double-blind, radiographic Axial Spondylarthritis (nr-axSpA) Placebo-Controlled Trial Study Sponsor Statement: Study funding Study Sponsor Statement: The study and provided by UCB. UCB did not play a role in the editorial support for the abstract (provided by conduct and reporting of the study. MedLogix Communications, LLC) were funded by Mallinckrodt Pharmaceuticals. 1874. Differences Between Men and Women in the Patient Pathways to Diagnosis of Ankylosing 1843. Integrated Efficacy of the AURORA 1 and Spondylitis AURA-LV Trials Confirms Voclosporin Rapid Study Sponsor Statement: This study was

53 sponsored by Novartis Pharmaceuticals 1890. Daily Management of Patients with Axial Corporation, East Hanover, NJ. Support for Spondyloarthritis: Self-monitoring of Disease third-party writing assistance for this abstract, Activity with a Smartphone App Is Feasible – a furnished by Eric Deutsch, PhD, of Health Proof of Concept Study Interactions, Inc, was provided by Novartis Study Sponsor Statement: This work was Pharmaceuticals Corporation, East Hanover, NJ. supported in part by Novartis. The Investigators retained full control of scientific and analytic 1880. Association of Healthcare Utilization and content, and had final editorial responsibility. Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis 1892. Pattern and Influential Factors in Study Sponsor Statement: This study was Promoting Treat-to-Target (T2T) for F funded by Novartis Pharmaceuticals Ankylosing Spondylitis (AS) Patients with the Corporation, East Hanover, NJ. Support for App of Smart System of Disease Management third-party writing assistance for this abstract, (SSDM): A Cohort Study from China furnished by Charli Dominguez, PhD, of Health Study Sponsor Statement: Smart system of Interactions, Inc, was provided by Novartis disease management (SSDM) was developed by Pharmaceuticals Corporation, East Hanover, NJ. Shanghai Gothic Internet Technology Co., Ltd.

1885. Performance of SASDAS (Simplified Axial 1893. Predictors of Response in Secukinumab- Spondyloarthritis Disease Activity Score) versus treated Patients with Ankylosing Spondylitis: ASDAS in a Post Hoc Analysis of a Randomized Logistic Regression and Machine Learning Controlled Clinical Trial Analyses Study Sponsor Statement: This study was Study Sponsor Statement: The study was sponsored by Pfizer. Medical writing support sponsored by Novartis Pharma AG, Basel, was provided by David Sunter, PhD CMPP of Switzerland. Engage Scientific Solutions and was funded by Pfizer. 1894. Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in 1887. Spinal Mobility and Function: How Patients with Chronic Back Pain Closely Do They Associate in Axial Study Sponsor Statement: The sponsor had no Spondyloarthropathy? role in conduct and reporting of the study. Study Sponsor Statement: Sponsorship for the ASRI provided by: AbbVie, Pfizer and UCB 1902. Determinants of Physician Global Assessment and Influence of Contextual Factors 1888. Successful Evaluation of Spinal Mobility in Early Axial Spondyloarthritis Measurements with the Epionics SPINE Device Study Sponsor Statement: DESIR is financially in Patients with Axial Spondyloarthritis supported by unrestricted grants from both the Compared to Controls French Society of Rheumatology and Pfizer Ltd Study Sponsor Statement: AbbVie sponsored France. this study and contributed to the design, study conduct, and analysis. AbbVie participated in 1904. Clinical Features of Patients with Active the interpretation of data, review, and approval Ankylosing Spondylitis Who Did Not Respond to of the Abstract. Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis

54

Study Sponsor Statement: Eli Lilly and Company Roche Ltd funded the study and was involved in was involved in study design, collection, conduct and reporting of the study. analysis and interpretation of data, and preparation of the submitted abstract. All 1926. Efficacy of Adjunctive Methotrexate in authors had full access to all data in the study Patients with Giant Cell Arteritis Treated with and had the final responsibility for the decision Tocilizumab Plus Prednisone Tapering: to submit for publication Subanalysis of a Phase 3 Trial Study Sponsor Statement: F Hoffmann-La 1908. Establishment of iPSc and Differentiated Roche Ltd funded the study and was involved in Endothelial Cells of Systemic Sclerosis conduct and reporting of the study. Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis 1963. Variation in Quality of Care Among Study Sponsor Statement: This work is Patient Sociodemographic Groups in RISE supported by grants from GlaxoSmithKline K.K. Practices and Actelion Pharmaceuticals Japan Ltd. Study Sponsor Statement: This data was supported by the ACR’s RISE Registry. However, 1909. High-density Proteomic Analysis of Skin the views expressed represent those of the Blister Fluid and Plasma in Systemic Sclerosis authors, not necessarily those of the ACR. Identifies Local and Systemic Differences for Key Proteins 1973. Treatment Sequences with Study Sponsor Statement: This study was Romosozumab Before or After Antiresorptive funded by GSK in collaboration with UCL Medication Study Sponsor Statement: This study was 1910. Integrated Molecular Analysis of sponsored by Amgen, Astellas, and UCB Pharma Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major 1974. Validation of a Deep Learning Based Autoantibody Subgroups Algorithm to Diagnose Vertebral Compression Study Sponsor Statement: Study was funded by Fractures GSK in collaboration with UCL Study Sponsor Statement: Amgen scientists designed the study and analyzed the data. 1916. KZR-616, a First-in-class Selective Amgen also provided compensation to Inhibitor of the Immunoproteasome, radiologists for the time used in reviewing Ameliorates Polymyositis in a Murine Model radiographs for this study. Study Sponsor Statement: The Groettrup laboratory has received financial support from 1978. Prevalence and Factors Associated with Kezar Life Sciences, Inc. Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy 1924. Low Immunogenicity in Patients with Study Sponsor Statement: Corrona has been Giant Cell Arteritis Treated with Tocilizumab: 3- supported through contracted subscriptions in Year Results from the Randomized Controlled the last 2 years by AbbVie, Amgen, Boehringer Portion and the Open-Label Follow-Up of a Ingelheim, Bristol-Myers Squibb, Celgene, Eli Phase 3 Trial Lilly and Company, Genentech, Gilead, Janssen, Study Sponsor Statement: F Hoffmann-La Merck, Novartis, Ortho Dermatologics, Pfizer Inc., Regeneron, and Sun.

55

provided by Frances Smith, PhD, of 2 the Nth, 1979. Participant Engagement and Adherence which was funded by AbbVie. in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported 1997. Immunogenicity of Adjuvanted Herpes Outcome Data Among Rheumatoid Arthritis Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Patients Treated with Janus Kinase Inhibitors Study Sponsor Statement: This study was and Controls: Preliminary Results funded by Eli Lilly and Company. Study Sponsor Statement: The study is an investigator initiated study whic has rpartly 1981. Patients with Inflammatory Arthritis Who funded by Pfeizer independend funds Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by 2002. Incidence and Risk Factors for Herpes Smartphone Apps: A Cross-sectional Study of Zoster in Rheumatoid Arthritis Patients 101 Patients, the ImBAIA Study Receiving Upadacitinib Study Sponsor Statement: Eli Lilly France, Study Sponsor Statement: AbbVie funded this Sandoz France and the French society of study, contributed to its design, and Physiotherapy participated in data collection, analysis and interpretation of the data 1990. Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile 2006. Identification of a Rule to Predict Dermatomyositis Response to Sarilumab in Patients with Study Sponsor Statement: Baricitinib provided Rheumatoid Arthritis Using Machine Learning by Eli Lilly and Company, expanded access and Clinical Trial Data program sponsor. Study Sponsor Statement: This study was sponsored by Sanofi. Medical writing support 1995. Non-invasive Vagus Nerve Stimulation was provided by Richard J Hogan, PhD Improves Signs and Symptoms of Rheumatoid (Eloquent Medical Affairs, a division of Envision Arthritis: Results of a Pilot Study Pharma Group), and funded by Sanofi. Study Sponsor Statement: This study was sponsored by Vorso Corp. 2007. Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 1996. Evaluation of Response to Pneumococcal (JAK1) by Filgotinib in Adults with Moderately- Vaccination in Patients with Rheumatoid to-Severely Active Rheumatoid Arthritis with Arthritis Receiving Upadacitinib: Results from a Prior Inadequate Response to Methotrexate Phase 2 Open-Label Extension Study Study Sponsor Statement: The sponsor (Gilead Study Sponsor Statement: AbbVie funded this Sciences, Inc.), participated in the FINCH 1 trial study and participated in the study design, design, and was responsible for coordinating research, analysis, data collection, the collection, management and analysis of the interpretation of data, reviewing, and approval data. The academic authors and sponsor of the publication. All authors had access to coauthors were responsible for drafting, relevant data and participated in the drafting, editing, and revising of the abstract. review, and approval of this publication. No honoraria or payments were made for 2011. Improves Patient Reported authorship. Medical writing assistance was Outcomes in Patients with Moderately to

56

Severely Active Rheumatoid Arthritis Damage and Long-term Clinical Outcomes with Inadequately Controlled by Methotrexate: Secukinumab Therapy in Patients with Psoriatic Results from the Double-Blind, Randomized Arthritis Controlled Phase III Study Study Sponsor Statement: The study was Study Sponsor Statement: JSC “R-Pharm sponsored by Novartis Pharma AG, Basel, International” sponsorship the study Switzerland. Academic advisors and Novartis personnel designed the study. Statisticians 2012. A Phase IIb, Randomized, Double-blind employed by Novartis conducted the data Study in Patients with Rheumatoid Arthritis analyses. All authors had access to the data and Evaluating the Safety and Efficacy of vouch for the completeness and accuracy of the Evobrutinib Compared with Placebo in Patients data and analyses. with an Inadequate Response to Methotrexate Study Sponsor Statement: This study was 2018. Development and Validation of an sponsored by EMD Serono Research & Artificial Intelligence Approach for the Development Institute, Inc., a business of Merck Detection of Radiographic Sacroiliitis KGaA, Darmstadt, Germany. The study sponsor Study Sponsor Statement: The PROOF study is was involved in the study design, collection, funded by AbbVie. analysis, and interpretation of data, and was GESPIC was initially supported by the German involved in the decision to submit the abstract Federal Ministry of Education and Research for publication. Bioscript Science provided (Bundesministerium für Bildung und medical writing support, funded by Merck Forschung—BMBF). As consequence of the KGaA, Darmstadt, Germany. funding reduction by BMBF according to schedule in 2005 and stopped in 2007, 2014. The Relative Diagnostic Utility of complementary financial support has been Inflammatory Back Pain Criteria in an Inception obtained also from Abbott, Amgen, Centocor, Cohort of Patients with Psoriasis, Iritis, and Schering–Plough, and Wyeth. Starting from Colitis Presenting with Undiagnosed Back Pain 2010, the core GESPIC cohort was supported by Study Sponsor Statement: Abbvie provided AbbVie. unrestricted funding but had no role in the conduct and reporting of the study. 2021. The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic 2015. Prevalence and Distribution of Peripheral Ultrasound Enthesitis Tool (DUET) Study Musculoskeletal Manifestations in Axial Study Sponsor Statement: This study was Spondyloarthritis, Peripheral Spondyloarthritis funded by an unrestricted research grant and Psoriatic Arthritis: Results of the through the Group for Research and International, Cross-sectional ASAS-PerSpA Assessment of Psoriasis and Psoriatic Arthritis Study (GRAPPA). The grant was collectively funded by Study Sponsor Statement: This study was the following pharmaceutical companies: Pfizer, conducted under the umbrella of ASAS with Novartis, Eli-Lilly, Janssen, and Abbvie. unrestricted grant of Abbvie, Pfizer, Lilly, Novartis, UCB, Janssen and Merck. 2022. Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – 2017. Machine Learning Identifies an Results from a Prospective Study Using PET-MRI Association Between Pre-existing Radiographic of SIJ and Spine

57

Study Sponsor Statement: This work was 2026. Efficacy and Safety of Upadacitinib versus supported by an unrestricted Grant from MSD Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate 2023. Efficacy and Safety of Upadacitinib in Response to Non-Biologic Disease-Modifying Patients with Active Ankylosing Spondylitis: 1- Anti-Rheumatic Drugs: A Double-Blind, Year Results from a Randomized, Double-Blind, Randomized Controlled Phase 3 Trial Placebo-Controlled Study with Open-Label Study Sponsor Statement: AbbVie Inc. was the Extension study sponsor, contributed to study design, Study Sponsor Statement: AbbVie funded this data collection, analysis & interpretation study and participated in the study design, research, analysis, data collection, 2027. Efficacy and Safety of Tildrakizumab, a interpretation of data, reviewing, and approval High-Affinity Anti–Interleukin-23p19 of the publication. All authors had access to Monoclonal Antibody, in Patients with Active relevant data and participated in the drafting, Psoriatic Arthritis in a Randomized, Double- review, and approval of this publication. No Blind, Placebo-Controlled, Multiple-Dose, Phase honoraria or payments were made for 2b Study authorship. Medical writing support was Study Sponsor Statement: Studies were funded provided by M Hovenden and J Matsuura of by Merck Sharp & Dohme Corp; analyses by Sun ICON plc and was funded by AbbVie. Pharmaceutical Industries, Inc.

2024. Effects of Filgotinib on Spinal Lesions in 2028. Predictors of Maintaining Inactive Patients with Ankylosing Spondylitis: Magnetic Disease After Etanercept Withdrawal, and Resonance Imaging Data from the Placebo- Regaining Inactive Disease Status After Flare Controlled, Double‑Blind, Randomized and Retreatment, in Adults with Non- TORTUGA Trial radiographic Axial Spondyloarthritis: Results Study Sponsor Statement: The TORTUGA trial from RE-EMBARK was sponsored by Galapagos NV and co-funded Study Sponsor Statement: This study was by Galapagos NV and Gilead Sciences, Inc. sponsored by Pfizer Medical writing support was provided by Debbie Sherwood BSc, CMPP (Aspire Scientific 2030. Treatment with Selective Ltd, Bollington, UK) and funded by Galapagos Cyclooxygenase-2 Inhibitors Is Associated with NV. Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term 2025. Efficacy of Guselkumab, a Monoclonal Results from the German Spondyloarthritis Antibody That Specifically Binds to the p19 Inception Cohort Subunit of IL-23, on Axial-Related Endpoints in Study Sponsor Statement: GESPIC was initially Patients with Active PsA with Imaging- supported by the German Federal Ministry of Confirmed Sacroiliitis: Week-52 Results from Education and Research (Bundesministerium für Two Phase 3, Randomized, Double-blind, Plac Bildung und Forschung—BMBF). As Study Sponsor Statement: Employees of the consequence of the funding reduction by BMBF sponsor were involved in designing the study, according to schedule in 2005 and stopped in collecting and analyzing the data, and writing 2007, complementary financial support has and revising the abstract. been obtained also from Abbott, Amgen, Centocor, Schering–Plough, and Wyeth. Starting

58 from 2010, the core GESPIC cohort was Publication Practice (GPP3) guidelines (Ann supported by AbbVie. Intern Med 2015;163:461-464).

2040. Continued Treatment with Nintedanib in L05. DMARD Changes for Patients with Patients with Systemic Sclerosis-Associated Rheumatoid Arthritis in the US During the First Interstitial Lung Disease (SSc-ILD): Interim Three Months of the COVID-19 Pandemic Analysis of SENSCIS-ON Study Sponsor Statement: Pfizer: The company Study Sponsor Statement: Boehringer had no role in the present study Ingelheim funded the SENSCIS-ON trial and was involved in its design and implementation and L06. (anti GM-CSF Receptor α in the interpretation of the data. Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 2052. Extended Follow-Up of Patients Recruited Trial of Patients with Giant Cell Arteritis to a Randomized, Controlled Trial of Rituximab Study Sponsor Statement: Role of the Study versus Azathioprine After Induction of Sponsor(s): Kiniksa Pharmaceuticals, Ltd. Remission with Rituximab for Patients with funded this study. ANCA-Associated Vasculitis and Relapsing Disease L07. Tocilizumab for COVID-19 Infection: A Study Sponsor Statement: Study was supported Randomized, Double-Blind, Placebo-Controlled by Roche and Genentech Trial Study Sponsor Statement: This was an L03. Efficacy and Safety of Deucravacitinib investigator-initiated trial. Genentech funded (BMS-986165), an Oral, Selective Tyrosine the trial and supplied tocilizumab, but had no Kinase 2 Inhibitor, in Patients with Active role in the trial design, conduct, analysis, or Psoriatic Arthritis: Results from a Phase 2, abstract preparation. Randomized, Double-Blind, Placebo-Controlled Trial L08. Long Term Cardiovascular Safety of Study Sponsor Statement: This study was Febuxostat and Allopurinol in Patients with sponsored by Bristol Myers Squibb. Professional Chronic Gout: The Febuxostat versus medical writing assistance was provided by Allopurinol Streamlined Trial (on Behalf of the Peloton Advantage, LLC, an OPEN Health FAST Investigators) company, and funded by Bristol Myers Squibb. Study Sponsor Statement: The study was funded by Menarini but the study sponsor was L04. Influenza Adverse Events in Patients with the University of Dundee and the funder had no Rheumatoid Arthritis in the Tofacitinib Clinical role in the running of the study. Program Study Sponsor Statement: This study was L09. A Phase 2a Randomized, Double-blind, sponsored by Pfizer Inc. Medical writing Placebo-controlled Study of Ziritaxestat in Early support, under the guidance of the authors, was Diffuse Cutaneous Systemic Sclerosis (NOVESA) provided by Kirsten Woollcott, PhD, CMC Study Sponsor Statement: NOVESA was Connect, McCann Health Medical sponsored by Galapagos NV and co‑funded by Communications and was funded by Pfizer Inc, Galapagos NV and Gilead Sciences, Inc. Medical New York, NY, USA in accordance with Good writing support was provided by Hannah Mace

59

MPharmacol, CMPP (Aspire Scientific Ltd, Analysis of a Phase 3, Randomized, Double- Bollington, UK) and funded by Galapagos NV. blind, Placebo-controlled Study Study Sponsor Statement: This study was L10. Targeting Plasmacytoid Dendritic Cells sponsored by Pfizer Inc. Medical writing Improves Cutaneous Lupus Erythematosus Skin support, under the guidance of the authors, was Lesions and Reduces Type I Interferon Levels: provided by Sarah Piggott, MChem, CMC Results of a Phase 1 Study of VIB7734 Connect, McCann Health Medical Study Sponsor Statement: Viela Bio, the study Communications and was funded by Pfizer Inc, sponsor, participated in the design of the study New York, NY, USA in accordance with Good and interpretation of the data. Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464). L11. Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary

60